

**1.0 Title Page**

**Statistical Analysis Plan**

**Study M13-542**

**A Phase 3, Randomized, Double-Blind Study  
Comparing Upadacitinib to Placebo on Stable  
Conventional Synthetic Disease-Modifying  
Anti-Rheumatic Drugs (csDMARDs) in Subjects with  
Moderately to Severely Active Rheumatoid Arthritis  
with Inadequate Response or Intolerance to Biologic  
DMARDs (bDMARDs)**

**Date: 18 Dec 2020**

**Version 3.0**

<b>2.0</b>	<b>Table of Contents</b>	
<b>1.0</b>	<b>Title Page</b> .....	<b>1</b>
<b>2.0</b>	<b>Table of Contents</b> .....	<b>2</b>
<b>3.0</b>	<b>Introduction</b> .....	<b>6</b>
<b>4.0</b>	<b>Study Objectives, Design and Procedures</b> .....	<b>6</b>
4.1	Study Objectives .....	6
4.2	Overall Study Design and Plan .....	6
4.3	Sample Size.....	13
4.4	Interim Analysis and Data Base Lock.....	14
4.5	Data Monitoring Committee (DMC) Activities.....	14
<b>5.0</b>	<b>Analysis Populations and Analysis Windows</b> .....	<b>14</b>
5.1	Analysis Populations.....	14
5.2	Analysis Windows .....	15
<b>6.0</b>	<b>Demographics, Baseline Characteristics, Medical History, and Previous/Concomitant Medications</b> .....	<b>17</b>
6.1	Demographics and Baseline Characteristics .....	17
6.2	Medical History .....	20
6.3	Prior Treatment and Concomitant Medications .....	20
6.4	Protocol Deviations.....	21
<b>7.0</b>	<b>Patient Disposition</b> .....	<b>21</b>
<b>8.0</b>	<b>Study Drug Exposure and Compliance</b> .....	<b>23</b>
8.1	Study Drug Exposure .....	23
8.2	Compliance .....	25
<b>9.0</b>	<b>Efficacy Analysis</b> .....	<b>25</b>
9.1	General Considerations .....	25
9.1.1	Efficacy Analysis at Different Phases of the Study .....	25
9.1.2	Definition of Missing Data Imputation.....	26
9.2	Efficacy Analysis by Week 12.....	28
9.2.1	Primary Efficacy Analysis .....	28
9.2.2	Sensitivity Analysis of Primary Efficacy Variables .....	29
9.2.3	Key Secondary Efficacy Analyses .....	29
9.2.4	Exploratory Efficacy Analyses .....	30

9.2.5	Handling of Multiplicity .....	32
9.2.6	Efficacy Subgroup Analysis .....	34
9.2.7	Summary of Efficacy Analysis by Week 12 .....	35
9.3	Long-Term Efficacy Analysis.....	38
9.4	Efficacy Variables Definitions and Conventions.....	40
9.4.1	ACR Criteria .....	40
9.4.2	Joint Evaluation .....	43
9.4.3	Patient's Global Assessment of Disease Activity Visual Analog Scale (VAS) .....	44
9.4.4	Physician's Global Assessment of Disease Activity Visual Analog Scale (VAS) .....	45
9.4.5	Patient's Global Assessment of Pain.....	45
9.4.6	Disease Activity Score (DAS28) .....	45
9.4.7	Simplified Disease Activity Index (SDAI) .....	46
9.4.8	Clinical Disease Activity Index (CDAI).....	46
9.4.9	Clinical Remission (CR) and Low Disease Activity (LDA).....	47
9.4.10	ACR/EULAR Boolean Remission.....	47
9.4.11	Disability Index of Health Assessment Questionnaire (HAQ-DI).....	47
9.4.12	EuroQoL-5D (EQ-5D-5L) .....	48
9.4.13	Insomnia Severity Index (ISI).....	48
9.4.14	Form SF-36v2 .....	49
<b>10.0</b>	<b>Safety Analysis .....</b>	<b>49</b>
10.1	General Considerations .....	49
10.2	Analysis of Adverse Events .....	51
10.2.1	Analysis of Adverse Events Prior to Protocol-Defined Treatment Switching .....	52
10.2.1.1	Adverse Events Overview.....	52
10.2.1.2	Adverse Events by System Organ Class and Preferred Term.....	53
10.2.1.3	TEAEs by Maximum Severity .....	53
10.2.1.4	TEAEs by Relationship.....	54
10.2.1.5	Frequent ( $\geq 2\%$ ) Adverse Events and Reasonably Possibly Related Adverse Events by System Organ Class and Preferred Term .....	54

10.2.1.6	Adverse Events of Special Interest .....	54
10.2.2	Analysis of Long-Term Adverse Event Rates .....	56
10.2.2.1	Overview of Adverse Events Rates per 100 Patient-Years of Study Drug Exposure .....	57
10.2.2.2	Adverse Events Rates per 100 Patient-Years of Study Drug Exposure by SOC and PT .....	58
10.2.2.3	Adverse Events of Special Interest Rates per 100 Patient-Years of Study Drug Exposure .....	59
10.2.2.4	Listing of Serious Adverse Events (Including Deaths) and Adverse Events Leading to Study Drug Discontinuation .....	59
10.3	Analysis of Laboratory Data .....	60
10.3.1	Variables and Units .....	60
10.3.2	Analysis of Laboratory Data by Week 12 .....	62
10.3.2.1	Assessment of Mean Change from Baseline and Percentage Change from Baseline in Clinical Laboratory Variables .....	62
10.3.2.2	Assessment of Shift from Baseline in Clinical Laboratory Variables .....	62
10.3.2.3	Assessment of Potentially Clinical Significant Laboratory Values .....	63
10.3.2.4	Assessment of Liver Elevations .....	63
10.3.3	Analysis of Long-Term Laboratory Data .....	64
10.3.3.1	Assessment of Mean Change from Baseline and Percentage Change from Baseline in Clinical Laboratory Variables .....	64
10.3.3.2	Assessment of Potentially Clinical Significant Laboratory Values .....	65
10.3.3.3	Assessment of Liver Elevations .....	66
10.4	Analysis of Vital Signs .....	66
10.4.1	Variables and Criteria Defining Abnormality .....	66
10.4.2	Analysis of Vital Sign by Week 12 .....	67
10.4.3	Analysis of Long-Term Vital Sign .....	67
<b>11.0</b>	<b>Summary of Changes .....</b>	<b>69</b>
11.1	Summary of Changes between the Previous Version and the Current Version .....	69
<b>12.0</b>	<b>Version History .....</b>	<b>70</b>
<b>13.0</b>	<b>Appendix .....</b>	<b>70</b>
<b>14.0</b>	<b>References .....</b>	<b>86</b>

## List of Tables

Table 1.	Analysis Windows for Efficacy Analysis for Period 1 (for ACR Components and Morning Stiffness) and Safety Analysis for Period 1 (for Labs and Vital Signs) .....	16
Table 2.	Analysis Windows for Efficacy Analysis for Period 1 (for EQ-5D-5L, SF-36, and ISI).....	16
Table 3.	Subgroups for Efficacy Analysis .....	35
Table 4.	Summary of Efficacy Variables and Corresponding Analyses for Efficacy Analysis by Week 12.....	36
Table 5.	Summary of Efficacy Variables and Corresponding Analyses for Long-Term Efficacy Analysis.....	40
Table 6.	Anatomical Joints Assessed for Calculation of Tender and Swollen Joint Counts (TJC68 and SJC66).....	44
Table 7.	Anatomical Joints for DAS28 (CRP) Calculation .....	46
Table 8.	AESI for Upadacitinib with SMQs/CMQs/PTs Searches.....	55
Table 9.	List of Laboratory Variables .....	60
Table 10.	Criteria for Potentially Clinically Significant Vital Sign Findings.....	67
Table 11.	SAP Version History Summary .....	70

## List of Figures

Figure 1.	Period 1 Study Design .....	9
Figure 2.	Period 2 Study Design .....	10
Figure 3.	Graphical Multiple Testing Procedure for US/FDA Regulatory Purposes .....	33
Figure 4.	Graphical Multiple Testing Procedure for EU/EMA Regulatory Purposes .....	34

## List of Appendices

Appendix A.	OMERACT Criteria.....	71
Appendix B.	Statistical Analysis to Account for Impact of COVID-19 Pandemic.....	84

### **3.0 Introduction**

This statistical analysis plan (SAP) describes the statistical analyses to be completed by the Data and Statistical Science Department for Upadacitinib Study M13-542. It provides details to further elaborate statistical methods as outlined in the protocol.

Pharmacokinetic and biomarker analyses will be performed separately and the corresponding analysis plan is documented separately.

Unless noted otherwise, all analyses will be performed using SAS version 9.2 or later (SAS Institute Inc., Cary, NC 27513) under the UNIX operating system.

### **4.0 Study Objectives, Design and Procedures**

#### **4.1 Study Objectives**

##### **Period 1**

To compare the safety and efficacy of Upadacitinib 30 mg QD and 15 mg QD versus placebo on a background of csDMARD(s) for the treatment of signs and symptoms of RA in bDMARD-inadequate response (bDMARD-IR) or bDMARD-intolerant subjects with moderately to severely active RA.

##### **Period 2**

To evaluate the long-term safety, tolerability, and efficacy of Upadacitinib 30 mg QD and 15 mg QD in subjects with RA who have completed Period 1.

#### **4.2 Overall Study Design and Plan**

This is a Phase 3, multicenter study that includes two periods. Period 1 is the 24-week randomized, double-blind, parallel-group, placebo-controlled period designed to compare the safety and efficacy of Upadacitinib 30 mg QD and 15 mg QD versus placebo for the treatment of signs and symptoms of subjects with moderately to severely active RA who have an inadequate response to or intolerance to bDMARD therapy and are currently on a stable dose of csDMARDs. Period 2 is a blinded long-term extension to evaluate the

long-term safety, tolerability, and efficacy of Upadacitinib 30 mg QD and 15 mg QD in subjects with RA who have completed Period 1. Starting with Amendment 4, all subjects will receive open-label upadacitinib 15 mg QD, including those currently on upadacitinib 30 mg QD.

The study is designed to enroll approximately 450 subjects at approximately 350 study centers worldwide to meet scientific and regulatory objectives without enrolling an undue number of subjects in alignment with ethical considerations. Therefore, if the target number of subjects has been enrolled, there is a possibility that additional subjects in screening may not be enrolled.

The study duration includes a 35-day screening period; a 24-week randomized, double-blind, parallel-group, placebo controlled treatment period (Period 1); a 236-week blinded extension period (Period 2); and a 30-day follow-up (call or site visit).

Subjects who meet eligibility criteria will be randomized in a 2:2:1:1 ratio to one of four treatment groups:

- Group 1: Upadacitinib 30 mg QD, N = 150 (Day 1 to Week 12) → Upadacitinib 30 mg QD (Week 12 and thereafter)
- Group 2: Upadacitinib 15 mg QD, N = 150 (Day 1 to Week 12) → Upadacitinib 15 mg QD (Week 12 and thereafter)
- Group 3: Placebo, N = 75 (Day 1 to Week 12) → Upadacitinib 30 mg QD (Week 12 and thereafter)
- Group 4: Placebo, N = 75 (Day 1 to Week 12) → Upadacitinib 15 mg QD (Week 12 and thereafter)

Randomization is stratified by number of prior bDMARD (stratum 1: failed 1 or 2 biologics with the same mechanism of action; stratum 2: failed  $\geq 3$  biologics with the same mechanism of action and/or multiple mechanisms of action) and geographic region.

Subjects must have been receiving csDMARD therapy  $\geq 3$  months and have been on a stable dose of csDMARD(s) for  $\geq 4$  weeks prior to the first dose of study drug and must

remain on a stable dose until Week 24; the csDMARD dose may be decreased only for safety reasons. Subjects who do not achieve  $CDAI \leq 10$  at Week 24 should have background medication(s) adjusted or initiated after assessments for Week 24 have been completed. Starting at Week 24 (after Week 24 assessments have been performed), initiation of or change in corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), acetaminophen, or adding or increasing doses in up to 2 csDMARDs (concomitant use of up to 2 csDMARDs except the combination of MTX and leflunomide) is allowed as per local label. Subjects on a combination of MTX and leflunomide therapy should discontinue either MTX or leflunomide prior to first dose of study drug administration per washout criteria defined in Section 5.2.3 of the protocol.


Subjects who complete the Week 24 visit (end of Period 1) will enter the blinded long-term extension portion of the study, Period 2 (236 weeks). Subjects who are assigned to Upadacitinib treatment groups in Period 1 will continue to receive Upadacitinib 15 mg QD or 30 mg QD per original randomization assignment in a blinded manner. Subjects who are assigned to placebo for the first 12 weeks of Period 1 and subsequently switched to receive Upadacitinib 15 mg QD or 30 mg QD per their pre-specified randomization assignments at Week 12, will continue to receive the same dose of Upadacitinib per original randomization assignment in a blinded manner. Starting with Amendment 4, all subjects will receive open-label upadacitinib 15 mg QD, including those currently on upadacitinib 30 mg QD.

An unblinded analysis will be conducted after all subjects have completed Period 1 (Week 24) for the purpose of regulatory submission. Study sites and subjects will remain blinded for the duration of the study (Periods 1 and 2).

Study design schematics of Period 1 and Period 2 are shown in [Figure 1](#) and [Figure 2](#), respectively.




**Figure 1. Period 1 Study Design**



csDMARD = conventional synthetic disease modifying anti-rheumatic drug; DMARD = disease modifying anti-rheumatic drug; n = number; QD = once daily; RA = rheumatoid arthritis; W = week

\* The follow-up period is only for subjects who do not enter Period 2.

**Figure 2. Period 2 Study Design**



csDMARD = conventional synthetic disease modifying anti-rheumatic drug; QD = once daily; W = week

Note: Starting with Amendment 4, all subjects will receive open-label upadacitinib 15 mg QD, including those currently on upadacitinib 30 mg QD.

### **Screening Period**

Within 35 days prior to the Baseline Visit, subjects will receive a full explanation of the study design and study procedures, provide a written informed consent, and undergo the screening procedures outlined in the protocol. Lab values can be re-tested once during the screening period. If the re-tested lab value(s) remain(s) exclusionary, the subject will be considered a screen failure with no additional re-screening possible. Redrawing samples if previous samples were unable to be analyzed would not count as a retest since previous result was never obtained.

Subjects that initially screen fail for the study are permitted to re-screen once following re-consent. Lab values can be re-tested once during the re-screening period. For additional re-screenings, AbbVie Therapeutic Area Medical Director approval is required. All screening procedures with the possible exceptions noted below will be repeated during re-screening. The subject must meet all the inclusion and none of the exclusion criteria at the time of re-screening in order to qualify for the study. There is no minimum period of time a subject must wait to re-screen for the study. If the subject had a complete initial screening evaluation including the assessment of an Interferon-Gamma Release Assay (IGRA; QuantiFERON Tuberculosis [TB] Gold In Tube test) and/or a purified protein derivative (PPD) test (or equivalent) (or both if required per local guidelines), or chest x-ray and electrocardiogram (ECG), these tests will not be required to be repeated for re-screening provided the conditions noted in the protocol are met, there are no changes in the subject's medical history that would warrant re-testing, and no more than 90 days have passed.

#### **Period 1 (24-Week Randomized, Double-Blind Treatment Period)**

Period 1 will begin at the Baseline Visit (Day 1) and will end at the Week 24 Visit. At the Baseline Visit, subjects who meet all the inclusion criteria and none of the exclusion criteria described in the protocol will be enrolled into the study and randomized to double-blind treatment. During this period of the study, subjects will visit the study site at Weeks 1, 2, 4, 8, 12, 16, 20, and 24. A  $\pm 3$  day window is permitted around scheduled study visits. The last dose of study drug in Period 1 is taken the day prior to the Week 24 visit. Subjects who complete Period 1, but decide not to continue in Period 2 should complete a 30 day follow-up visit after the last dose of study drug.

#### **Period 2 (Blinded Long-Term Extension Period [236 Weeks])**

Period 2 will begin at the Week 24 Visit after all assessments have been completed. During Period 2, subjects will have a study visit at Weeks 36, 48, and every 12 weeks through Week 240, and Week 260/PD. A  $\pm 7$  day window is permitted around scheduled study visits.

Starting at Week 24, at least 20% improvement in BOTH TJC AND SJC is required to remain on study drug. Anyone who does not fulfill this criterion at 2 consecutive visits (starting at Week 24) despite optimization of background RA therapy must be discontinued from study drug.

Starting with Amendment 4, all subjects will receive open-label upadacitinib 15 mg QD, including those currently on upadacitinib 30 mg QD.

### **Discontinuation of Study Drug and Continuation of Study Participation Period 1 and Period 2)**

Subjects may discontinue study drug treatment but may choose to continue to participate in the study. Subjects who prematurely discontinue study drug should complete a Premature Discontinuation visit (PD visit) as soon as possible, preferably within 2 weeks. To minimize missing data for efficacy and safety assessments, subjects who prematurely discontinue study drug treatment should continue to be followed for all regularly scheduled visits as outlined in the protocol, unless subjects have decided to discontinue study participation entirely (withdrawal of informed consent). Subjects should be advised on the continued scientific importance of their data even if they discontinue treatment with study drug early. Following discontinuation of study drug, the subject should be treated in accordance with the investigator's best clinical judgment irrespective of whether the subject decides to continue participation in the study. As the subject has discontinued study drug, all rescue and efficacy driven discontinuation criteria no longer apply (e.g., CDAI calculation at Week 24, 20% TJC/SJC calculation for PD). If at any point a subject no longer wants to provide assessments (withdrawal of informed consent) following discontinuation of study drug, a second (PD visit) is not required.

### **Premature Discontinuation of Study (Withdrawal of Informed Consent) (Period 1 and Period 2)**

Subjects may withdraw from the study completely (withdrawal of informed consent) for any reason at any time. If a subject prematurely discontinues study drug treatment and study participation (withdrawal of informed consent), the procedures outlined for the

Premature Discontinuation visit (PD visit) should be completed as soon as possible, preferably within 2 weeks of study drug discontinuation. In addition, if the subject is willing, a 30-day follow-up phone call may occur to determine the status of any ongoing AEs/SAEs or the occurrence of any new AEs/SAEs.

### **Follow-Up Visit**

A Follow-Up Visit will occur approximately 30 days after the last dose of study drug to obtain information on any new or ongoing AE/SAEs, and to collect vital signs and clinical laboratory tests.

Subjects will complete the Follow-Up Visit when they have either

- Completed the last visit of Period 1 (Week 24), but decided not to participate in the extension Period 2; OR
- Completed the last visit of Period 2; OR
- Prematurely discontinued study drug and/or study participation and have completed a PD visit. In this case the 30 day Follow-Up visit may be a telephone call if a site visit is not possible. Vital signs and laboratory test may not be required. The Follow-Up visit is not applicable for subjects who discontinued study drug and continued study participation and completed at least one study visit at least approximately 30 days after last dose of study drug.

## **4.3 Sample Size**

The planned total sample size of 450 can provide approximately 90% power to detect a 20% difference in ACR20 rates at Week 12 (assuming a placebo ACR20 response rate of 27%), at two-sided  $\alpha = 0.025$  and accounting for 10% dropout rate. This sample size also provides approximately 90% power for a 17% difference in DAS28 (CRP) LDA response rate at Week 12 (assuming a placebo DAS28 LDA response rate of 12%), at two-sided  $\alpha = 0.025$  and accounting for 10% dropout rate. It can also provide at least 90% power

for most key secondary endpoints, at two-sided significance level of 0.025 and accounting for a 10% dropout rate.

#### **4.4 Interim Analysis and Data Base Lock**

An unblinded analysis will be conducted after all subjects have completed Period 1 (Week 24) for the purpose of regulatory submission. Study sites and subjects will remain blinded for the duration of the study (Periods 1 and 2).

#### **4.5 Data Monitoring Committee (DMC) Activities**

An independent external Data Monitoring Committee (DMC) is used to review unblinded safety data at regular intervals during the conduct of the study. The DMC will provide recommendation to an AbbVie Point of Contact on whether to continue, modify, or terminate studies after each review. When needed, high-level unblinded efficacy data may also be requested by the DMC and be reviewed so that the DMC can assess benefit:risk of any emerging safety differences.

### **5.0 Analysis Populations and Analysis Windows**

#### **5.1 Analysis Populations**

##### **Full Analysis Set (FAS)**

The Full Analysis Set (FAS) includes all randomized subjects who received at least one dose of study drug. The FAS will be used for all efficacy and baseline analyses.

##### **Per Protocol Analysis Set**

The Per Protocol Analysis Set represents a subset of the FAS and consists of all FAS subjects who did not meet any major protocol deviations up to Week 12 in Period 1 of the study. Additional analysis of the primary efficacy endpoint will be conducted on the Per Protocol analysis set, in order to evaluate the impact of major protocol deviations.

Major protocol deviations (ICH deviation and other clinically significant non-ICH deviation) will be identified prior to database lock.

### **Safety Analysis Set**

The Safety Analysis Set consists of all subjects who received at least one dose of study drug. For the Safety Analysis Set, subjects are assigned to a treatment group based on the "as treated" treatment group, regardless of the treatment randomized. The "as treated" is determined by the treatment the subject received during the majority of the subject's drug exposure time in the analysis period.

## **5.2 Analysis Windows**

### **Definition of Study Days (Days Relative to the First Dose of Study Drug)**

Study Days are calculated for each collection date relative to the date of the first dose of study drug. It is defined as the number of days between the date of the first dose of study drug and the collection date. Study days are negative values when the collection date of interest is prior to the first study drug dose date. Study days are positive values when the collection date of interest is on or after the first study drug dose date. The day of the first dose of study drug is defined as Study Day 1, while the day prior to the first study drug dose is defined as Study Day -1 (there is no Study Day 0). Study days are used to map actual study visits to the protocol-specified study visits.

### **Definition of Analysis Windows**

The following rules will be applied to assign actual subject visits to protocol-specified visits. For each protocol-specified study visit, a target study day will be identified to represent the corresponding visit along with a window around the target day. Windows will be selected in a non-overlapping fashion so that a collection date does not fall into multiple visit windows. If a subject has two or more actual visits in one visit window, the visit closest to the target day will be used for analysis. If two visits are equidistant from the target day, then the later visit will be used for analysis.

The visit window and the target study day for each protocol-specified visit in Period 1 are displayed in Table 1 and Table 2 (depending on the different visit schedules of different endpoints). Visit windows for protocol-specified visits in Period 2 are defined similarly.

**Table 1. Analysis Windows for Efficacy Analysis for Period 1 (for ACR Components and Morning Stiffness) and Safety Analysis for Period 1 (for Labs and Vital Signs)**

Protocol Specified Visit Week	Lower Bound	Target Day	Upper Bound
Baseline	-99	1 <sup>a</sup>	1
1	2	8	11
2	12	15	22
4	23	29	43
8	44	57	71
12	72	85	first dose date from Week 12 dispensed kit
16	first dose date from Week 12 dispensed kit + 1	113	127
20	128	141	155
24	156	169	first dose date of Period 2

a. Day of first dose of study drug.

**Table 2. Analysis Windows for Efficacy Analysis for Period 1 (for EQ-5D-5L, SF-36, and ISI)**

Protocol Specified Visit Week	Lower Bound	Target Day	Upper Bound
Baseline	-99	1 <sup>a</sup>	1
4	2	29	57
12	58	85	first dose date from Week 12 dispensed kit
24	first dose date from Week 12 dispensed kit + 1	169	first dose date of Period 2

a. Day of first dose of study drug.



## **6.0 Demographics, Baseline Characteristics, Medical History, and Previous/Concomitant Medications**

### **6.1 Demographics and Baseline Characteristics**

Demographic and baseline characteristics information will be collected at the Baseline visit of the study and will be summarized for the FAS. The number of observations, mean, standard deviation, median, minimum and maximum will be summarized for continuous variables. Categorical or discrete variables will be summarized via frequencies and percentages. Summary statistics will be computed for each treatment group and overall.

#### **Main Demographic and Baseline Characteristics**

- Sex (male, female)
- Age (years)
- Age Categories (< 40, [40, 65), ≥ 65 years)
- Race (White, Black or African American, American Indian or Alaska Native, Native Hawaiian or Other Pacific Islander, Asian, Other)
- Geographic Region (North America, South/Central America, Western Europe, Eastern Europe, Asia, Other)
- Ethnicity (Hispanic or Latino, Not Hispanic or Latino)
- Weight (kg)
- Weight Categories (< 60 kg, ≥ 60 kg)
- Height (cm)
- Body Mass Index (BMI) (kg/m<sup>2</sup>)
- Body Mass Index (BMI) Category (kg/m<sup>2</sup>) (BMI < 25, BMI ≥ 25)

#### **RA Medical History and Characteristics**

- Duration of RA Symptoms in years
- Duration of RA Diagnosis in years
- Duration of RA Categories (< 10 year, ≥ 10 year)

- Number of prior bDMARD received (1, 2,  $\geq 3$ )
- Prior failed bDMARD (stratum 1: failed 1 or 2 biologics with the same mechanism of action; stratum 2: failed  $\geq 3$  biologics with the same mechanism of action and/or multiple mechanisms of action)
- Failed at least one prior bDMARD due to lack of efficacy (yes, no)
- Failed at least one anti-TNF (yes, no)
- Corticosteroids use at baseline (yes, no)
- Oral steroid dosing (prednisone equivalent) at baseline
- Concomitant csDMARD at baseline (MTX alone, MTX and other csDMARD, csDMARD other than MTX)

#### **ACR and/or DAS Components at Baseline**

- Tender joint count (TJC68) defined as the number of tender joints out of 68 assessed joints
- Swollen joint count (SJC66) defined as the number of swollen joints out of 66 assessed joints
- Tender joint count (TJC28) defined as the number of tender joints out of 28 assessed joints used for DAS28 calculation
- Swollen joint count (SJC28) defined as the number of swollen joints out of 28 assessed joints used for DAS28 calculation
- Physician's global assessment of disease activity (mm on a 100-mm horizontal visual analogue scale [VAS])
- Patient's assessment of pain within last week (mm on a 100-mm horizontal VAS)
- Patient's global assessment of disease activity within last 24 hours (mm on a 100-mm horizontal VAS)
- Health Assessment Questionnaire Disability Index of the (HAQ – DI) (range: 0 to 3)
- High sensitivity C-reactive protein (hsCRP) (mg/L)
- Erythrocyte sedimentation rate (ESR) (mm/hr)

### **Other Baseline RA Disease Characteristics**

- Anti-cyclic citrulliated peptide (Anti-CCP) (units)
- Anti-CCP status: Positive or Negative
- Rheumatoid Factor (RF) (units)
- Rheumatoid Factor (RF) status: Positive or Negative
- DAS28 [hsCRP]
- DAS28 [ESR]
- DAS28 Categories:
  - DAS28 > 5.1 (High Disease Activity)
  - DAS28 ≤ 5.1
- Clinical Disease Activity Index (CDAI)
- CDAI categories:
  - CDAI > 22 (High Disease Activity)
  - CDAI ≤ 22
- Simplified Disease Activity Index (SDAI)
- SDAI categories:
  - SDAI > 26 (High Disease Activity)
  - SDAI ≤ 26

### **Patient Report Outcomes at Baseline**

- Morning stiffness (severity and duration)
- EQ-5D-5L
- ISI (sleep)
- 36-Item Short Form Health Survey (SF-36) Version 2: physical component summary, mental component summary and the 8 sub-domain scores

### **Clinical Tests at Screening**

- Chest x-ray
- ECG

- Tuberculin PPD skin test, QuantiFERON TB Gold test
- Hepatitis Testing
- Serum pregnancy test

### **Immunization History**

- BCG immunization
- Herpes Zoster immunization
- Hepatitis B immunization

### **Tobacco/Nicotine and Alcohol Use**

- Tobacco/Nicotine Use [user, ex-user, non-user, unknown]
- Alcohol Use [drinker, ex-drinker, non-drinker, unknown]

## **6.2 Medical History**

Medical history data will be summarized and presented for FAS population using body systems and conditions/diagnoses as captured on the CRF. The body systems will be presented in alphabetical order and the conditions/diagnoses will be presented in alphabetical order within each body system. The number and percentage of subjects with a particular condition/diagnosis will be summarized for each randomized treatment group as well as overall. Subjects reporting more than one condition/diagnosis within a body system will be counted only once for that body system. No statistical comparison will be performed for medical history reporting.

## **6.3 Prior Treatment and Concomitant Medications**

Prior and concomitant medications will be summarized by each randomized treatment group as well as overall for FAS. Prior medications are those medications taken prior to the first dose of study drug. This includes medications with a start date before the first study drug administration date, regardless of the end date of these medications. Medications taken on the day of the first dose of study drug are not counted as prior

medications. Concomitant medications are those medications, other than study drug, taken after the first dose of study drug and within 1 day of the last dose of study drug. This includes medications with a start date between first study drug administration and last study drug administration + 1 day, as well as, medications with a start date prior to first dose of study drug and which are ongoing after first dose of study drug. Medications taken on the day of the first dose of study drug are counted as concomitant medications.

The number and percentage of subjects who received a prior medication and the number and percentage of subjects who received a concomitant medication will be tabulated separately by the generic name assigned by the most current version of the World Health Organization (WHO) Drug Dictionary.

#### **6.4 Protocol Deviations**

Protocol deviations based on ICH deviation criteria are categorized as follows:

1. Those who entered the study even though they did not satisfy the entry criteria
2. Those who developed withdrawal criteria during the study and were not withdrawn
3. Those who received the wrong treatment or incorrect dose, and
4. Those who received an excluded or prohibited concomitant medication.

The protocol deviations listed above will be summarized and listed by treatment group.

#### **7.0 Patient Disposition**

The following will be summarized by randomized treatment group as well as overall:

- number of subjects randomized,
- number of subjects included in key analysis populations (Full Analysis Set and Per Protocol Analysis Set for primary efficacy analysis, Safety Analysis Set for analysis prior to Week 12 treatment switching),
- number of subjects who completed Period 1 study participation,

- number of subjects who entered Period 2,
- number of subjects who completed overall study (Period 1 and Period 2) participation (not applicable for Period 1 reporting).

This summary will be repeated by site.

Premature discontinuation details will be further summarized separately for Period 1 and Period 2 as follows.

### **Period 1**

The number and percentage of subjects completed Period 1 and prematurely discontinued in Period 1 will be summarized by randomized treatment group, separately by study drug and study participation completion/discontinuation, with the primary reason for discontinuation collected from CRF by the following categories:

- Adverse event (AE)
- Withdrew consent
- Lost to follow-up
- Lack of efficacy
- Other.

Subjects may have more than one reason for discontinuing, but only the primary reason will be summarized.

In addition, the number and percentage of subjects enrolled in Period 2 will also be summarized by randomized treatment group.

### **Period 2**

Period 2 patient dispositions and reason for discontinuation will be summarized for overall and by treatment regimen when entering Period 2 defined as follows:

1. Upadacitinib 15 mg QD

## 2. Upadacitinib 30 mg QD

Among the subjects who entered Period 2 participation (regardless of whether subject prematurely discontinued study drug in Period 1), the number and percentage of subjects completed and prematurely discontinued study participation in Period 2 will be summarized. Among the subjects who entered Period 2 upon completion of study drug in Period 1, the number and percentage of subjects completed and prematurely discontinued study drug in Period 2 will be summarized.

For subjects who prematurely discontinued study drug or study participation, the primary reason as well as all reasons for discontinuation will be summarized by the following categories (as collected in CRF):

- Adverse event (AE)
- Withdrew consent
- Lost to follow-up
- Lack of efficacy
- Other

### **Summary of Dose Switch from Upadacitinib 30 mg QD to 15 mg QD**

Starting with Amendment 4, all subjects will receive open-label upadacitinib 15 mg QD, including those currently on upadacitinib 30 mg QD. The visit at which dose switch occurs could be different for each subject. For subjects on upadacitinib 30 mg QD in Period 2, the number and percentage of subjects switching to upadacitinib 15 mg QD at each visit will be summarized.

## **8.0 Study Drug Exposure and Compliance**

### **8.1 Study Drug Exposure**

The duration of exposure to study drug will be summarized for the safety analysis set by the following groups.

1. Placebo

2. Upadacitinib 15 mg QD

This includes Upadacitinib 15 mg QD exposure from subjects starting on Upadacitinib 15 mg QD and subjects switching from placebo to Upadacitinib 15 mg QD.

3. Upadacitinib 30 mg QD

4. This includes Upadacitinib 30 mg QD exposure from subjects starting on Upadacitinib 30 mg QD and subjects switching from placebo to Upadacitinib 30 mg QD. Exposure is censored at time of dose switch from Upadacitinib 30 mg QD to Upadacitinib 15 mg QD. Upadacitinib 15 mg QD switched from Upadacitinib 30 mg QD

This includes Upadacitinib 15 mg QD exposure from subjects who switched dose from Upadacitinib 30 mg QD to Upadacitinib 15 mg QD.

Starting with Amendment 4, all subjects will receive open-label upadacitinib 15 mg QD, including those currently on upadacitinib 30 mg QD. Exposure to upadacitinib 30 mg QD (Group 3) will be censored prior to the day subject received the first dose of upadacitinib 15 mg QD, and subsequent exposure to upadacitinib 15 mg QD will be summarized under a separate group (Group 4).

The duration of exposure to study drug will be summarized for each group as specified above, with the number of subjects, mean, standard deviation, median, minimum and maximum values. In addition, the number and percentage of subjects exposed to study drug will be summarized for the following cumulative duration intervals.

- $\geq 2$  weeks
- $\geq 1$  month
- $\geq 3$  months
- $\geq 6$  months



- $\geq 9$  months
- $\geq 12$  months
- $\geq 18$  months
- $\geq 2$  years
- $\geq 2.5$  years
- $\geq 3$  years
- $\geq 4$  years

## **8.2 Compliance**

Study drug compliance will be summarized for each treatment group for Period 1. The compliance is defined as the number of tablets taken (i.e., the difference between the number of tablets dispensed and the number of tablets returned) during the subject's participation in Period 1 divided by the number of days that the subject was in the Treatment Phase of Period 1.

## **9.0 Efficacy Analysis**

### **9.1 General Considerations**

There are two sets of planned efficacy analysis: efficacy analysis by Week 12 and long-term efficacy analysis. All efficacy analyses will be carried out using the FAS population.

#### **9.1.1 Efficacy Analysis at Different Phases of the Study**

##### **Efficacy Analysis by Week 12**

Standard efficacy analysis by randomized treatment groups (Upadacitinib 15 mg QD, Upadacitinib 30 mg QD and the combined placebo groups) will be performed on efficacy data up to Week 12. No protocol-defined treatment switching will occur prior to the time point. Formal statistical inference will be generated, and results from this set of analysis will be used as the key efficacy findings of this study.

### **Long-Term Efficacy Analysis**

Long-term efficacy analysis will be performed on As Observed data (defined in Section 9.1.2) by randomized treatment group sequence as described below:

1. Placebo → Upadacitinib 15 mg QD
2. Placebo → Upadacitinib 30 mg QD
3. Upadacitinib 15 mg QD
4. Upadacitinib 30 mg QD

There will be no statistical testing; only descriptive statistics and confidence intervals will be provided.

Starting with Amendment 4, all subjects will receive open-label upadacitinib 15 mg QD, including those currently on upadacitinib 30 mg QD. For long-term efficacy analysis, subjects will continue to be summarized under the treatment sequences as described above, regardless of dose switch – i.e., for treatment sequences 2 and 4, data collected after dose switch will continue to be summarized under the same treatment sequences. The visit at which dose switch occurs could be different for each subject. The first and last visits at which dose switch occurs will be noted in the summary.

#### **9.1.2 Definition of Missing Data Imputation**

##### **Non-Responder Imputation (NRI) Approach**

The NRI approach will categorize any subject who has a missing value for categorical variables at a specific visit as non-responder for that visit. In addition, subjects who prematurely discontinue from study drug will be considered as non-responders for all subsequent visits after discontinuation.

### **Observed Cases (OC)**

The OC analysis will not impute values for missing evaluations. In addition, the OC will not use values after premature discontinuation of study drug. This sensitivity analysis will only be applied to the analysis prior to treatment switching.

### **As Observed (AO)**

The AO analysis will not impute values for missing evaluations. Regardless of treatment switching or premature discontinuation of study drug, all observed data will be used in the analysis. The AO analysis will be applied to long-term efficacy analysis.

### **Mixed Effect Model Repeat Measurement (MMRM) for Short-Term Analysis**

The repeated measure analysis will be conducted using mixed model including observed measurements at all visits. The mixed model includes the categorical fixed effects of treatment, visit and treatment-by-visit interaction, main stratification factors at randomization and the continuous fixed covariates of baseline measurement. An unstructured variance covariance matrix will be used. The parameter estimations are based on the assumption of data being missing at random and using the method of restrictive maximum likelihood (REML). The missing at random assumption is considered reasonable given the high placebo response rate typically seen in RA trials. Additionally in RA trials, the proportion of discontinuation is relatively small (10 – 15% only) and the rate of discontinuation due to lack of efficacy is generally low (< 5%).

### **MMRM and Generalized Linear Mixed Model (GLMM) for Long-Term Analysis**

The repeated measure analysis will be conducted using mixed model including As Observed measurements at all visits. MMRM will be used for continuous endpoints and GLMM will be used for binary endpoints. The mixed models will include the categorical fixed effects of treatment, visit and treatment-by-visit interaction, and main stratification factor prior bDMARD use. For the MMRM analysis of change from baseline in continuous endpoints, the baseline measurement will be included as a continuous fixed covariate. The categorical fixed effect of subject's discontinuation status may also be

included in the model as appropriate. Unstructured, Toeplitz, compound symmetry, or other covariance structures may be considered.

### **Multiple Imputation (MI)**

The MI analysis will impute missing data multiple times under appropriate random variation and thus generate multiple imputed "pseudo-complete" datasets. Results will be aggregated across the multiple imputed datasets, overcoming drawbacks of the single imputation methods. LOCF will be first applied to augment data into monotonic missing pattern and PROC MI will be used to generate 5 datasets using the regression method. Specifically, visits will be imputed in order, where later visits are imputed by regressing upon all previous visits, baseline, treatment group, demographics and other key baseline characteristics. Analysis will first be performed on each of the multiple imputed datasets, and PROC MIANALYZE will then be used to aggregate the results for the final statistical inference. The imputation is based on the assumption of data being missing at random. The missing at random assumption is considered reasonable given the high placebo response rate typically seen in RA trials. Additionally in RA trials, the proportion of discontinuation is relatively small (10 – 15% only) and the rate of discontinuation due to lack of efficacy is generally low (< 5%).

## **9.2 Efficacy Analysis by Week 12**

### **9.2.1 Primary Efficacy Analysis**

The primary endpoint for US/FDA regulatory purposes is ACR20 response at Week 12. The primary endpoint for EU/EMA regulatory purposes is LDA (based on DAS28 (CRP)  $\leq 3.2$ ) at Week 12. Analyses will be conducted separately for US/FDA regulatory purposes and EU/EMA regulatory purposes; for each set of analysis, only one primary endpoint is specified.

Analysis of the primary endpoint will be conducted on the FAS based on randomized treatment groups (Upadacitinib 15 mg QD, Upadacitinib 30 mg QD and the combined placebo groups). Point estimate and 95% CI using normal approximation will be

provided for the response rate for each randomized treatment group. Comparisons of the primary endpoint will be made between each Upadacitinib dose and the combined placebo group using the Cochran-Mantel-Haenszel test adjusting for stratification factor prior bMDARD use. Point estimate, 95% CI using normal approximation and p-value for the treatment comparison will be presented. Both the nominal p-value constructed using the Cochran-Mantel-Haenszel test and the adjusted p-value through the graphical multiplicity procedure described in Section 9.2.5 will be provided. For the primary analysis, non-responder imputation (NRI) will be used.

### **9.2.2 Sensitivity Analysis of Primary Efficacy Variables**

The primary analysis for point estimate and CI will be repeated using Observed Cases without any imputation as a sensitivity analysis. This will be conducted on the FAS based on randomized treatment groups.

Supportive NRI analysis will also be conducted on the Per Protocol Analysis Set.

### **9.2.3 Key Secondary Efficacy Analyses**

Ranked key secondary endpoints (at Week 12) for US/FDA regulatory purposes are:

1. Change from baseline in DAS28 (CRP);
2. Change from baseline in HAQ-DI;
3. LDA as measured by DAS28 (CRP);
4. Change from baseline in SF-36 Physical Component Score (PCS).

Ranked key secondary endpoints (at Week 12) for EU/EMA regulatory purposes are:

1. Change from baseline in DAS28 (CRP);
2. ACR20 response rate;
3. Change from baseline in HAQ-DI;

4. Change from baseline in SF-36 Physical Component Score (PCS).

Other key secondary endpoints (at Week 12) for both US/FDA and EU/EMA regulatory purposes are:

1. ACR50 response rate;
2. ACR70 response rate;
3. ACR20 response rate at Week 1.

For binary endpoints, frequencies and percentages will be reported for each randomized treatment group. Similar analyses as for the primary endpoint will be conducted.

For the major RA continuous endpoints DAS28 and HAQ-DI change from baseline, statistical inference will be conducted using analysis of covariance (ANCOVA) coupled with MI for missing data handling. Specifically, the ANCOVA model will include treatment as the fixed factor, and the corresponding baseline value and the stratification factor prior bDMARD use (Yes/No) as the covariates. For other continuous endpoints, statistical inference will be conducted using the MMRM model as described in Section 9.1.2, with the main stratification factor being prior bDMARD use (Yes/No). From both the MI and MMRM analyses, the LS mean and 95% CI will be reported for each randomized treatment group; the LS mean treatment difference and associated 95% CI and p-value will be reported comparing each Upadacitinib dose group with the combined placebo group. Both nominal p-value and adjusted p-value through the graphical multiplicity procedure described in Section 9.2.5 will be provided.

#### **9.2.4 Exploratory Efficacy Analyses**

Additional efficacy analysis includes the following endpoints at Week 1, 2, 4, 8 and 12:

- Change from baseline in individual components of ACR response;
- ACR20/50/70 response rates;

- Change from baseline in DAS28 (CRP) and DAS28 (erythrocyte sedimentation rate [ESR]);
- Change from baseline in CDAI and SDAI;
- Change from baseline in morning stiffness (severity and duration);
- Proportion of subjects achieving LDA and proportion of subjects achieving CR based on DAS28 (CRP), DAS28 (ESR), Simplified Disease Activity Index (SDAI), and CDAI criteria;
- Proportion of subjects achieving MCID in change from baseline in HAQ-DI (defined as change from baseline in HAQ-DI  $\leq -0.3$ ) among those with baseline HAQ-DI  $\geq 0.3$ ;
- ACR/EULAR Boolean remission.

Additional endpoints (at Weeks 4 and 12) are:

- Change from baseline in EQ-5D-5L;
- Change from baseline in ISI (sleep);
- Change from baseline in SF-36.

For binary endpoints, point estimate and 95% CI using normal approximation will be provided for the response rate for each randomized treatment group. Point estimate, 95% CI and p-value will be provided for the treatment comparison between each Upadacitinib dose group and the combined placebo group using the Cochran-Mantel-Haenszel test adjusting for stratification factor prior bDMARD use. Only the nominal p-value will be provided, and the 95% CI will be based on normal approximation. NRI will be used as primary analysis and OC will be used as sensitivity analysis.

For continuous endpoints, the LS mean and 95% CI will be reported for each randomized treatment group. The LS mean treatment difference and associated 95% CI and p-values between each Upadacitinib dose group and the combined placebo group will be provided using MMRM model with fixed effects of treatment, visit and treatment-by-visit interaction, prior bDMARD use and baseline value as covariate. Only the nominal p-value will be provided.


### 9.2.5 Handling of Multiplicity

The overall type I error rate of the primary and ranked key secondary endpoints for the two doses will be strongly controlled using a graphical multiple testing procedure.<sup>1</sup> Specifically, the testing will utilize the endpoint sequence of primary endpoint followed by the ranked key secondary endpoints in the order as specified in Section 9.2.3, and will begin with testing the primary endpoint using  $\alpha$  of 0.025 for each dose. Continued testing will follow a pre-specified  $\alpha$  transfer path which includes downstream transfer along the endpoint sequence within each dose as well as cross-dose transfer. Adjusted p-values for the primary and ranked key secondary endpoints will be provided based on the testing procedure.


The graphs for the testing procedures are provided in Figure 3 and Figure 4, for US/FDA and EU/EMA regulatory purposes respectively. In the graph, the arrows specify the  $\alpha$  transfer paths. Once an endpoint is rejected (i.e., deemed significant) at its assigned significance level, its significance level will be transferred to subsequent endpoint(s) following the arrow(s). The numbers on the arrows denote the weights for transferring significance levels. Specifically, the weight 1 denotes 100% transfer of significance level.



**Figure 3. Graphical Multiple Testing Procedure for US/FDA Regulatory Purposes**



**Figure 4. Graphical Multiple Testing Procedure for EU/EMA Regulatory Purposes**



### 9.2.6 Efficacy Subgroup Analysis

The primary efficacy endpoint will be examined in the subgroups listed in [Table 3](#) below. Treatment difference between each Upadacitinib dose and the combined placebo group will be presented with point estimate and 95% confidence interval using normal approximation. No p-value will be provided for subgroup analysis. If any of the resulting subgroups has fewer than 10% of the planned study size (i.e., < 45 subjects), the subgroup analyses for that variable will not be presented.

**Table 3. Subgroups for Efficacy Analysis**

Subgroup Factor	Categories
Age	< 40, [40, 65), ≥ 65
Sex	Male or Female
Weight	< 60 kg or ≥ 60 kg
BMI	< 25 or ≥ 25
Race	White, Black or African American, American Indian or Alaska Native, Native Hawaiian or Other Pacific Islander, Asian, Other
Geographic Region	North America, South/Central America, Western Europe, Eastern Europe, Asia, Other
Duration of RA diagnosis	< 10 year or ≥ 10 year
Baseline Rheumatoid Factor Status	Positive or Negative
Baseline Anti-CCP Antibody Status	Positive or Negative
Baseline both RF positive and Anti-CCP positive	Yes or No
Baseline DAS28[hsCRP)	≤ 5.1 or > 5.1
Prior failed bDMARD	stratum 1: failed 1 or 2 biologics with the same mechanism of action; stratum 2: failed ≥ 3 biologics with the same mechanism of action and/or multiple mechanisms of action
Failed at least one Prior bDMARD due to lack of efficacy	Yes or No
Failed anti-IL6 due to lack of efficacy	Yes or No

### 9.2.7 Summary of Efficacy Analysis by Week 12

Table 4 below provides the overview of the efficacy analyses by Week 12 to be performed on different endpoints.

**Table 4. Summary of Efficacy Variables and Corresponding Analyses for Efficacy Analysis by Week 12**

Efficacy Variables	Analysis Method
<b>Primary Variables</b>	
<ul style="list-style-type: none"> <li>• ACR20 response at Week 12<sup>a</sup></li> <li>• LDA as measured by DAS28(CRP) at Week 12<sup>b</sup></li> </ul>	<ul style="list-style-type: none"> <li>• Point estimate and 95% CI of the response rate for each Upadacitinib dose group and the combined placebo group. The 95% CI will be based on normal approximation.</li> <li>• Point estimate, 95% CI and p-value for the treatment comparison between each Upadacitinib dose group and the combined placebo group, where the p-value is constructed using the Cochran-Mantel-Haenszel test adjusting for stratification factor prior bDMARD use. Both nominal p-value and adjusted p-value through the graphical multiplicity procedure described in Section 9.2.5 will be provided. The 95% CI will be based on normal approximation.</li> <li>• Subgroup analysis.</li> <li>• Imputation: NRI for primary analysis and OC for sensitivity analysis</li> <li>• Analysis Set: FAS and Per Protocol Analysis Set as supportive analysis (NRI only).</li> </ul>
<b>Key Secondary Variables</b>	
<p><b>Binary Endpoints:</b></p> <ul style="list-style-type: none"> <li>• ACR50/70 response at Week 12</li> <li>• ACR20 response at Week 12<sup>b</sup></li> <li>• LDA as measured by DAS28(CRP) at Week 12<sup>a</sup></li> <li>• ACR20 response at Week 1</li> </ul>	<ul style="list-style-type: none"> <li>• Point estimate and 95% CI of the response rate for each treatment group. The 95% CI will be based on normal approximation.</li> <li>• Point estimate, 95% CI and p-value for the treatment comparison between each Upadacitinib dose group and the combined placebo group using the Cochran-Mantel-Haenszel test adjusting for stratification factor prior bDMARD use. For ranked key secondary endpoints, both nominal p-value and adjusted p-value through the graphical multiplicity procedure described in Section 9.2.5 will be provided. The 95% CI will be based on normal approximation.</li> <li>• Imputation: NRI for primary analysis and OC for sensitivity analysis</li> <li>• Analysis Set: FAS</li> </ul>

**Table 4. Summary of Efficacy Variables and Corresponding Analyses for Efficacy Analysis by Week 12 (Continued)**

Efficacy Variables	Analysis Method
<b>Key Secondary Variables (Continued)</b>	
<b>Continuous Endpoints:</b> <ul style="list-style-type: none"> <li>• Change from baseline in DAS28(CRP) at Week 12</li> <li>• Change from baseline in HAQ-DI at Week 12</li> </ul>	<ul style="list-style-type: none"> <li>• LS mean, and 95% CI within each treatment group and LS mean, 95% CI and p-values between each Upadacitinib dose group and the combined placebo group using ANCOVA model with treatment, prior bDMARD use and baseline value as covariates. Both nominal p-value and adjusted p-value through the graphical multiplicity procedure described in Section 9.2.5 will be provided.</li> <li>• Imputation: MI</li> <li>• Analysis Set: FAS</li> </ul>
Change from baseline in SF-36 Physical Component Score (PCS) at Week 12	<ul style="list-style-type: none"> <li>• LS mean and 95% CI within each treatment group and LS mean, 95% CI and p-values between each Upadacitinib dose group and the combined placebo group using MMRM model with fixed effects of treatment, visit and treatment-by-visit interaction, prior bDMARD use and baseline value as covariate. Both nominal p-value and adjusted p-value through the graphical multiplicity procedure described in Section 9.2.5 will be provided.</li> <li>• Analysis Set: FAS</li> </ul>
<b>Additional Variables (summarized at all visits up to Week 12)</b>	
<b>Binary Endpoints:</b> <ul style="list-style-type: none"> <li>• ACR20/50/70</li> <li>• LDA and CR based on DAS28(CRP), DAS28 (ESR), SDAI, and CDAI criteria</li> <li>• Proportion of subjects achieving MCID in change from baseline in HAQ-DI among those with baseline HAQ-DI <math>\geq 0.3</math>;</li> <li>• ACR/EULAR Boolean remission;</li> </ul>	<ul style="list-style-type: none"> <li>• Point estimate and 95% CI of the response rate for each treatment group. The 95% CI will be based on normal approximation.</li> <li>• Point estimate, 95% CI and p-value for the treatment comparison between each Upadacitinib dose group and the combined placebo group using the Cochran-Mantel-Haenszel test adjusting for stratification factor prior bDMARD use. Only nominal p-value will be provided, and the 95% CI will be based on normal approximation.</li> <li>• Imputation: NRI for primary analysis and OC for sensitivity analysis</li> <li>• Analysis Set: FAS</li> </ul>

**Table 4. Summary of Efficacy Variables and Corresponding Analyses for Efficacy Analysis by Week 12 (Continued)**

Efficacy Variables	Analysis Method
<b>Additional Variables (summarized at all visits up to Week 12) (Continued)</b>	
<b>Continuous Endpoints:</b> <ul style="list-style-type: none"> <li>• Change from baseline in individual ACR components</li> <li>• Change from baseline in DAS28 (CRP) and DAS28 (ESR)</li> <li>• Change from baseline in CDAI and SDAI</li> <li>• Change from baseline in morning stiffness (severity and duration)</li> <li>• Change from baseline in EQ-5D-5L</li> <li>• Change from baseline in ISI (sleep)</li> <li>• Change from baseline in SF-36</li> </ul>	<ul style="list-style-type: none"> <li>• LS mean and 95% CI within each treatment group and LS mean, 95% CI and p-values between each Upadacitinib dose group and the combined placebo group using MMRM model with fixed effects of treatment, visit and treatment-by-visit interaction, prior bDMARD use and baseline value as covariate. Only nominal p-value will be provided.</li> <li>• Analysis Set: FAS</li> </ul>

- a. US/FDA regulatory purposes.  
 b. EU/EMA regulatory purposes.

### 9.3 Long-Term Efficacy Analysis

Assessments to evaluate long-term efficacy will be analyzed for the following measures at Week 1, 2, 4, 8, 12, 24, 36, 48, every 12 weeks through Week 240, and at Week 260.

- ACR20/50/70 response rates;
- Change from baseline in individual ACR components;
- Change from baseline in DAS28 (CRP);
- Change from baseline in DAS28 (ESR);
- Change from baseline in CDAI;
- Change from baseline in SDAI;
- Change from baseline in morning stiffness (severity and duration);
- Proportion of subjects achieving LDA and proportion of subjects achieving CR based on DAS28 (CRP), DAS28 (ESR), SDAI, and CDAI criteria;
- Proportion of subjects achieving MCID in change from baseline in HAQ-DI (defined as change from baseline in HAQ-DI  $\leq -0.3$ );

- ACR/EULAR Boolean remission;
- Proportion of subjects with no concomitant corticosteroid use (among subjects with corticosteroid use at baseline).

Assessments to evaluate long-term efficacy will be analyzed for the following measures at Week 4, 12, 24, 48:

- Change from baseline in EQ-5D-5L;
- Change from baseline in ISI (sleep);
- Change from baseline in SF-36.

Analyses will be based on As Observed (AO) data. Descriptive statistics will be provided for each randomized treatment group sequence as defined in Section 9.1.1. These include the number of observations, mean, standard deviation, and 95% CI for continuous endpoints; and frequencies and percentages with 95% CI using normal approximation for binary endpoints. In addition, longitudinal analysis will be performed using MMRM or GLMM as described in Section 9.1.2 for all endpoints except proportion of subjects with no concomitant corticosteroid use. Point estimates and 95% CI from the model will be provided for each treatment group sequence. Plot for each randomized treatment group sequence over time will be provided.

For the purpose of Period 1 CSR, response rate and 95% CI using NRI for binary endpoints will be provided for each randomized treatment group sequence by visits up to Week 24. For continuous endpoints, the LS mean and 95% CI based on MMRM will be reported for each randomized treatment group sequence by visits up to Week 24.

Table 5 below provides the overview of the long-term efficacy analyses to be performed on different endpoints.

**Table 5. Summary of Efficacy Variables and Corresponding Analyses for Long-Term Efficacy Analysis**

<b>Efficacy Variables</b>	<b>Analysis Method</b>
<b>Binary Endpoints:</b>	
<ul style="list-style-type: none"> <li>• ACR20/50/70 response by visit</li> <li>• LDA and CR based on DAS28(CRP), DAS28 (ESR), SDAI, and CDAI criteria by visit</li> <li>• Proportion of subjects with change from baseline in HAQ-DI <math>\leq -0.3</math> and <math>\leq -0.22</math>, respectively</li> <li>• Boolean remission</li> <li>• Proportion of subjects with no concomitant corticosteroid use (among subjects with corticosteroid use at baseline)*</li> </ul>	<ul style="list-style-type: none"> <li>• Point estimate and 95% CI of the response rate for each randomized treatment group sequence</li> <li>• Point estimate and 95% CI of the response rate using GLMM model for each randomized treatment group sequence (*endpoint excluded from this analysis)</li> <li>• Plot for each randomized treatment group sequence over time for key endpoints#</li> <li>• Imputation: AO</li> <li>• Analysis Set: FAS</li> </ul>
<b>Continuous Endpoints:</b>	
<ul style="list-style-type: none"> <li>• Change from baseline in individual ACR components by visit</li> <li>• Change from baseline in DAS28 (CRP) and DAS28(ESR) by visit</li> <li>• Change from baseline in CDAI and SDAI by visit</li> <li>• Change from baseline in morning stiffness (severity and duration) by visit</li> <li>• Change from baseline in EQ-5D-5L by visit</li> <li>• Change from baseline in ISI (sleep) by visit</li> <li>• Change from baseline in SF-36 by visit</li> </ul>	<ul style="list-style-type: none"> <li>• Point estimate, and 95% CI of mean change from baseline together with SD for each randomized treatment group sequence</li> <li>• Point estimate and 95% CI of change from baseline using MMRM model for each randomized treatment group sequence</li> <li>• Plot for each randomized treatment group sequence over time for key endpoints#</li> <li>• Imputation: AO Analysis Set: FAS</li> </ul>

# Key endpoints for figures include: ACR20/50/70, LDA and CR based on DAS28(CRP) and CDAI criteria, Boolean remission, change from baseline in DAS28(CRP) and CDAI.

Note: NRI for binary endpoints and MMRM for continuous endpoints were used for analysis up to Week 24, as described in this section. The analyses had been completed prior to SAP Version 3.0 and is no longer mentioned in [Table 5](#) for streamlined summary of future long-term efficacy analysis.

## 9.4 Efficacy Variables Definitions and Conventions

### 9.4.1 ACR Criteria

ACR criteria are a commonly used standard criteria set mentioned in the guidance of American College of Rheumatology to evaluate the effectiveness of investigation drug in



RA clinical trials. It is a composite measurement calculated based on the improvement over a set of core measurements.

ACR20 is defined as at least 20% improvement (compared to baseline values) in tender and swollen joint counts and at least 20% improvement in 3 of the remaining 5 core set measures (subject global assessment of pain, subject global assessment of disease activity, physician global assessment of disease activity, subject assessment of physical function and acute phase reactant hsCRP).

ACR50 and ACR70 are similarly defined with at least 50% and 70% improvement, respectively.

A subject will be classified as an ACR20 (ACR50, ACR70) responder, if the following conditions are met:

1.  $\geq 20\%$  (50%, 70%) improvement from baseline in tender joint count (TJC68) and
2.  $\geq 20\%$  (50%, 70%) improvement from baseline in swollen joint count (SJC66) and
3.  $\geq 20\%$  (50%, 70%) improvement from baseline in at least 3 of the following 5:
  - patient's assessment of pain
  - patient's global assessment of disease activity (PGA)
  - physician's global assessment of disease activity (PhGA)
  - patient's self-assessment of physical function (i.e., measured by Health Assessment Questionnaire HAQ-DI score)
  - Acute-phase reactant value CRP

There are seven components to be evaluated to define an ACR response. Missing values for each component can occur due to a missed visit or due to dropout from the study. Depending on the pattern of the missing components, ACR responses may be or may not be determined using observed values only.

To maximize the utilization of observed information at certain visits and be scientifically as robust as possible, the principle to calculate ACR response is to minimize imputation whenever possible. Observed ACR response will be calculated first based on a derived visit window instead of the nominal visit identifier (e.g., Week 6 visit) collected from the CRF.

To calculate observed ACR responses:

- Identify the observed component xx% improvement indicator (0/1/missing), 1 means achieving  $\geq$  xx% improvement from baseline and 0 means  $<$  xx% improvement from baseline (e.g., xx% representing 20%/50%/70%).
- $ACR_{xx} = 0$  if TJC indicator = 0 OR SJC indicator = 0 OR at least 3 out of 5 components improvement indicators = 0.
- $ACR_{xx} = 1$  if TJC indicator = 1 AND SJC indicator = 1 AND at least 3 out of 5 components improvement indicators = 1.
- For all other cases,  $ACR_{xx} =$  missing since  $ACR_{xx}$  cannot be determined.

The following table illustrates examples for ACR calculations.

Example	TJC 68	SJC 66	Component 1	Component 2	Component 3	Component 4	Component 5	ACR20-Response?
A	1	1	1	1	1	.	.	Yes
B	1	0	1	1	1	1	1	No
C	.	0	.	.	.	.	.	No
D	1	.	1	1	1	1	1	.
E	1	1	0	0	0	1	1	No
F	.	.	0	0	0	.	.	No
G	1	1	1	1	0	0	.	.

Legend: 1 =  $\geq$  20% improved compared to baseline; 0 =  $<$  20% improved compared to baseline; "." Missing

Windowing Rule for ACR Response Calculation:

- ACR component values will first be determined at each date within a visit window.

- ACR component values at each date will be combined to determine the observed ACR composite score at each date in each window.
- After this calculation, if multiple non-missing ACR composite scores are available within a given visit window, the non-missing ACR composite score closest to the target day will be used. If two composite scores have the same distance from the target day, the later one will be used. The corresponding date will be used as the observed ACR response date in the derived efficacy dataset.
- If a non-missing ACR composite score is not available for any day within a given visit window, the windowed component values for that visit will be used to calculate the ACR composite score for that visit window (component value windowing follow the same rules as in steps described above). The date of observed ACR composite score will be determined by the first available ACR component date, in the order of TJC, SJC, Pain, PGA, PhGA, HAQ-DI, CRP/ESR, in the derived efficacy dataset.

When observed ACR xx response for a given visit is missing, imputation methods will be used to calculate "imputed" ACRxx response.

- Non-Responder Imputation (NRI) for ACR response:
  - Step 1: all missing components will be imputed using LOCF, and then the ACR composite score can be calculated.
  - Step 2: if the ACR composite score cannot be determined by step 1, the ACR composite score will be imputed as 0. In addition, subjects who prematurely discontinue from the study drug will be considered as non-responders (ACR = 0) for all subsequent visits after the discontinuation date.

#### 9.4.2 Joint Evaluation

Anatomical joints are evaluated for swelling and tenderness at every study visit. The 34 anatomical joints in [Table 6](#) are assessed in this study for both the left and right side of the body.

**Table 6. Anatomical Joints Assessed for Calculation of Tender and Swollen Joint Counts (TJC68 and SJC66)**

<b>Temporomandibular</b>	<b>Sternoclavicular</b>	<b>Acromio-clavicular</b>	<b>Shoulder</b>
Elbow	Wrist	Metacarpophalangeal I	Metacarpophalangeal II
Metacarpophalangeal III	Metacarpophalangeal IV	Metacarpophalangeal V	Thumb Interphalangeal
Proximal Interphalangeal II	Proximal Interphalangeal III	Proximal Interphalangeal IV	Proximal Interphalangeal V
Distal Interphalangeal II	Distal Interphalangeal III	Distal Interphalangeal IV	Distal Interphalangeal V
Hip <sup>a</sup>	Knee	Ankle	Tarsus
Metatarsophalangeal I	Metatarsophalangeal II	Metatarsophalangeal III	Metatarsophalangeal IV
Metatarsophalangeal V	Great Toe/Hallux	Interphalangeal II	Interphalangeal III
Interphalangeal IV	Interphalangeal V		

a. Hip joints are not assessed for swelling.

At each study visit, a joint evaluator assessed whether a particular joint was "tender or painful" where presence of tenderness was scored as "1" and the absence of tenderness was scored as "0," provided the joint was not replaced ("9") or could not be assessed ("NA") due to other reasons (e.g., post-corticosteroid joint injection). The total tender joint count (TJC68), which is based on 68 joints, will be derived as the sum of all "1s" and proportional extrapolation will be used to impute joint counts for the joints that are replaced or not assessed. A similar method will be followed for the derivation of total swollen joint count (SJC66), which is based on 66 joints as the hip joints are excluded. Thus, the range for TJC68 will be 0 to 68 and 0 to 66 for SJC66.

### **9.4.3 Patient's Global Assessment of Disease Activity Visual Analog Scale (VAS)**

The subject will assess his/her disease activity for the past 24 hours using a Patient's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100.

#### **9.4.4 Physician's Global Assessment of Disease Activity Visual Analog Scale (VAS)**

The physician will assess Patient's disease activity at the time of visit using a Physician's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100.

#### **9.4.5 Patient's Global Assessment of Pain**

The subject will assess his/her pain in the previous week using a Patient's Global Assessment Pain VAS. The range is 0 to 100 mm with no pain being indicated by 0 and severe pain by 100.

#### **9.4.6 Disease Activity Score (DAS28)**

DAS28 (CRP) and DAS28 (ESR) are composite indices to assess disease activity in RA patients using hsCRP or ESR measurement respectively. The DAS provides a score between 0 and 10, indicating how active the rheumatoid arthritis is at the time of measurement.

DAS28 (CRP) and DAS28 (ESR) can be calculated based on Tender Joint Count, Swollen Joint Count, Patient's Global Assessment of Disease Activity (PtGA) (in mm), and hsCRP (in mg/L) or ESR (mm/hr).

$$\text{DAS28 (CRP)} = 0.56 \times \sqrt{(\text{TJC28}^*)} + 0.28 \times \sqrt{(\text{SJC28}^{**})} + 0.36 \times \ln(\text{hsCRP}^{\&} + 1) + 0.014 \times \text{PtGA}^{\gg} + 0.96$$

$$\text{DAS28 (ESR)} = 0.56 \times \sqrt{(\text{TJC28}^*)} + 0.28 \times \sqrt{(\text{SJC28}^{**})} + 0.70 \times \ln(\text{ESR}^{\#}) + 0.014 \times \text{PtGA}^{\gg}$$

\* TJC28 refers to the Subject's total Tender Joint Count out of the provided 28 evaluated joints.

\*\* SJC28 refers to the Subject's total Swollen Joint Count out of the provided 28 evaluated joints.

& hsCRP refers to the high-sensitivity c-reactive protein lab value. hsCRP unit in the DAS28 (CRP) equation is expressed as mg/L.

# ESR refers to the Erythrocyte sedimentation rate. ESR unit in the DAS28 (ESR) equation is expressed as mm/hr.

» PtGA refers to the Patient's Global Assessment of Disease Activity.

where  $\sqrt{\quad}$  is square root and  $\ln$  is natural log.

**Table 7. Anatomical Joints for DAS28 (CRP) Calculation**

<b>Shoulder</b>	<b>Elbow</b>	<b>Wrist</b>	<b>Thumb Interphalangeal</b>
Metacarpophalangeal I	Metacarpophalangeal II	Metacarpophalangeal III	Metacarpophalangeal IV
Metacarpophalangeal V	Proximal Interphalangeal II	Proximal Interphalangeal III	Proximal Interphalangeal IV
Proximal Interphalangeal V	Knee		

To calculate observed DAS28 scores, the observed component value will be calculated first. Then the components will be included in the calculation per the DAS formula selected. If any observed component is missing in a window, then the observed DAS28 score will be missing.

#### **9.4.7 Simplified Disease Activity Index (SDAI)**

SDAI is a composite continuous index to assess disease activity based on TJC28, SJC28, Patient's Global Assessment of Disease Activity (PtGA) (in cm, 0 – 10), Physician's Global Assessment of Disease Activity (PhGA) (in cm, 0 – 10) and hsCRP (mg/dL). It can be derived as follows:

$$\text{SDAI} = \text{TJC28} + \text{SJC28} + \text{PtGA (cm)} + \text{PhGA (cm)} + \text{hsCRP (mg/dL)}.$$

To calculate observed SDAI scores, the observed component value will be calculated first. Then the components will be included in the calculation per the SDAI formula selected. If any observed component is missing in a window, then the observed SDAI score will be missing.

#### **9.4.8 Clinical Disease Activity Index (CDAI)**

CDAI is a composite continuous index to assess disease activity without using hsCRP measurement. It can be calculated based on TJC28, SJC28, Patient's Global Assessment of Disease Activity (PtGA) (in cm, 0 – 10) and Physician's Global Assessment of Disease Activity (PhGA) (in cm, 0 – 10). It can be derived as follows:

$CDAI = TJC28 + SJC28 + PtGA (cm) + PhGA (cm).$

To calculate observed CDAI scores, the observed component value will be calculated first. Then the components will be included in the calculation per the CDAI formula selected. If any observed component is missing in a window, then the observed CDAI score will be missing.

#### 9.4.9 Clinical Remission (CR) and Low Disease Activity (LDA)

Clinical remission (CR) and low disease activity (LDA) based on DAS28 (CRP), DAS28(ESR), SDAI and CDAI are defined as follows:

	DAS28 (CRP) and DAS28 (ESR)	SDAI	CDAI
LDA	$\leq 3.2$	$\leq 11.0$	$\leq 10$
CR	$< 2.6$	$\leq 3.3$	$\leq 2.8$

#### 9.4.10 ACR/EULAR Boolean Remission

ACR/EULAR Boolean remission is defined based on the following four criteria:

- Tender joint count  $\leq 1$  (based on 28 joints)
- Swollen joint count  $\leq 1$  (based on 28 joints)
- CRP  $\leq 1$  mg/dL
- Patient global assessment of disease activity  $\leq 10$  (mm)

All four criteria must be satisfied at a visit for a subject to be classified as achieving ACR/EULAR Boolean remission.

#### 9.4.11 Disability Index of Health Assessment Questionnaire (HAQ-DI)

HAQ-DI is a self-reported patient outcome measurement. It is calculated as the mean of the scores from 8 following categories with a range 0 – 3: Dressing and Grooming,

Rising, Eating, Walking, Hygiene, Reach, Grip, and Activities. The higher the score, the more likely to associate with morbidity and mortality for the RA patient.

The maximum score for all the questions in each category is considered as the score for the category. The Standard disability index (HAQ-DI) takes into account the subject's use of aids or devices or assistance in the scoring algorithm for a disability category. For each of the eight disability categories there is an AIDS OR DEVICES companion variable(s) that is used to record the type of assistance, if any, a subject uses for his/her usual activities. If aids or devices and/or assistance from another person are checked for a disability category, the score for this category is set to 2 (much difficulty), if the original score is 0 (no difficulty) or 1 (some difficulty). The HAQ-DI is then calculated by summing the adjusted categories scores and dividing by the number of categories answered. The HAQ-DI cannot be calculated if the patient does not have scores for at least 6 categories.

#### **9.4.12 EuroQoL-5D (EQ-5D-5L)**

EQ-5D is a standardized measure of health status developed by the EuroQol Group in order to provide a simple, generic measure of health for clinical and economic appraisal. The EQ-5D consists of 2 pages. The first page measures 5 dimensions of the health status (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) with 5 levels per dimension (no problems, slight problems, moderate problems, severe problems, and extreme problems corresponding to Level 1 to Level 5 respectively). The second page is an EQ Visual Analogue Scale (EQ VAS). EQ-5D health states, defined by the EQ-5D-5L descriptive system on the first page, may be converted into a single index value. The change from baseline of the index value and EQ VAS will be analyzed and reported. UK scoring algorithm will be used.

#### **9.4.13 Insomnia Severity Index (ISI)**

ISI is a 7 item questionnaire that assess, (1) difficulty with sleep onset, (2) difficulty with sleep maintenance (3) problem with early awakening, (4) satisfaction with sleep pattern, (5) interference with daily functioning as a result of sleep problems, (6) noticeability of



sleep problem to others, and (7) degree of distress caused by sleep problem. The severity of insomnia items are rated on a likert type of scale, (0) "None," 1- "Mild," 2- "Moderate," 3- "Severe" and 4- "Very Severe." Other items on satisfaction, noticeability on impairment, worry/distress about sleep and interference are similarly rated on 5-point likert type scale form. The scoring algorithm is in the protocol.

#### **9.4.14 Form SF-36v2**

The 36-Item Short Form, Version 2 (SF-36v2) Questionnaire with 4 week recall will be completed by the subject at Baseline, Weeks 4, 8 and at study completion (Week 12 or at PD). The SF-36v2 health survey consists of 36 general health questions and this study is using the form for 4 weeks recall period (standard form). It has 2 components: physical and mental. For each component, a transformed summary score is calculated using 8 sub domains: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health.

The coding and scoring for the SF-36 will use the software provided by QualityMetrics.

## **10.0 Safety Analysis**

### **10.1 General Considerations**

Safety analyses will be carried out using the Safety Analysis Set. There are two sets of planned safety analysis: safety analysis by Week 12, and long-term safety analysis.

#### **Safety Analysis by Week 12**

Standard safety analysis by the "as treated" treatment groups of Upadacitinib 15 mg QD, Upadacitinib 30 mg QD, and combined placebo groups will be performed on safety data up to Week 12. No protocol-defined treatment switching will occur prior to these time points.

The standard safety analyses will include reporting of adverse events (AEs), laboratory, and vital signs measurements. Frequency tables of subjects with treatment-emergent

adverse events (TEAEs) by system organ class (SOC) and by preferred term (PT) as in the Medical Dictionary for Regulatory Activities (MedDRA) dictionary will be provided by treatment group. Mean changes from baseline in all continuous laboratory parameters and vital signs variables at each visit will be summarized by "as treated" treatment group. Frequency tables of subjects meeting criteria for potentially clinically significant vital sign values and for potentially clinically significant laboratory values will be provided by treatment group. Missing safety data will not be imputed.

### **Long-Term Safety Analysis**

Long-term safety analyses that account for protocol-defined treatment switching include reporting of AE rate adjusted by cumulative exposure, mean change from baseline in laboratory parameters and vital sign variables, and rate of potentially clinically significant laboratory and vital signs values. The treatment-emergent adverse event (TEAE) rate per 100 patient-years of exposure will be presented by actual treatment received at the time of AE (as described in Section 10.2.2). Listing of subjects with TEAEs by SOC and PT will be provided. Mean changes from baseline in all continuous laboratory parameters and vital signs variables at each visit will be summarized by "as treated" treatment group sequences defined as follows (as described in Section 10.3.3 and Section 10.4.3). Frequency tables and listings of subjects meeting criteria for potentially clinically significant vital sign values and for potentially clinically significant laboratory values will be provided by actual treatment received at the time of event. Missing safety data will not be imputed.

"As treated" treatment group sequences:

1. Placebo → Upadacitinib 15 mg QD
2. Placebo → Upadacitinib 30 mg QD
3. Upadacitinib 15 mg QD
4. Upadacitinib 30 mg QD.

Starting with Amendment 4, all subjects will receive open-label upadacitinib 15 mg QD, including those currently on upadacitinib 30 mg QD. For subjects who previously received upadacitinib 30 mg QD, adverse events and exposure to upadacitinib 30 mg QD will be censored at the time of dose switch; subsequent adverse events and exposure starting the day of first dose of upadacitinib 15 mg QD will be summarized under a separate group, as defined in Section 9.1. Assessment of potentially clinically significant laboratory and vital sign values will be based on the same treatment exposure groups as for adverse events, as described above. For summary of mean change from baseline in laboratory values and vital signs, exposure sequences 2 and 4 (i.e., subjects who switched from upadacitinib 30 mg QD to 15 mg QD) will be censored at the time of dose switch. Mean change from baseline for laboratory values and vital signs collected after dose switch will be summarized separately by visits post switch.

## **10.2 Analysis of Adverse Events**

A treatment-emergent Adverse Event (TEAE) is defined as an adverse event with an onset date that is after the first dose of study drug, and no more than 30 days of the drug after the last dose of study drug.

Events where the onset date is the same as the study drug start date are assumed to be treatment-emergent, unless the study drug start time and the adverse event start time are collected and the adverse event start time is prior to the study drug start time. If an incomplete onset date was collected for an adverse event, the event will be assumed to be treatment-emergent unless there is other evidence that confirms that the event was not treatment-emergent (e.g., the event end date was prior to the study drug start date).

Adverse event data will be presented by SOCs and PTs using MedDRA Version 19.1 or most up to date version. All adverse event tables will be sorted in alphabetical order by SOC and PT and descending percentages for each treatment group.

## **10.2.1 Analysis of Adverse Events Prior to Protocol-Defined Treatment Switching**

### **10.2.1.1 Adverse Events Overview**

The number and percentage of subjects experiencing TEAEs will be summarized by "as treated" treatment group and overall for the following AE categories.

- All TEAEs
- Treatment-emergent serious adverse events (SAEs)
- Treatment-emergent severe adverse events
- TEAEs reasonably possibly related to study drug
- TEAEs of special interest
- TEAEs leading to discontinuation of study drug
- TEAE leading to death

In the AE overview summary, any event with an unknown severity will be considered as severe and any AE with an unknown relationship will be considered as having "reasonable possibility" of being related to study drug.

Additional AEs may be considered for tabulation/summary based on recommendations from Clinical and Safety as deemed appropriate.

For TEAEs of special interest, the point estimate and 95% CI (using normal approximation) will be provided for the treatment difference in AE percentage between each Upadacitinib dose group and the combined placebo group.

As a sensitivity analysis, the AE overview summary will be repeated by randomized treatment groups (Upadacitinib 15 mg QD, Upadacitinib 30 mg QD and the combined placebo groups). In this summary, all AEs with an onset date after the first dose of study drug will be included, regardless of whether the AE occurred more than 30 days after the last dose of study drug.

### **10.2.1.2 Adverse Events by System Organ Class and Preferred Term**

The number and percentage of subjects experiencing adverse events will be tabulated by SOC and MedDRA PT by "as treated" treatment group and overall. The SOCs will be presented in alphabetical order, and the PTs will be presented in alphabetical order within each SOC.

The following summaries of adverse events will be generated:

- All TEAEs
- Treatment-emergent serious adverse events (SAEs)
- Treatment-emergent severe adverse events
- TEAEs reasonably possibly related to study drug
- TEAEs leading to discontinuation of study drug
- TEAE leading to death
- Frequent AEs (reported in 2% of subjects or more in any treatment group)

Subjects reporting more than one adverse event for a given MedDRA preferred term will be counted only once for that term (most severe incident for the severity tables and most related incident for the relationship tables). Subjects reporting more than one type of adverse event within a SOC will be counted only once for that SOC. Subjects reporting more than one type of adverse event will be counted only once in the overall total.

As a sensitivity analysis, the AE summary by SOC and PT will be repeated by randomized treatment groups (Upadacitinib 15 mg QD, Upadacitinib 30 mg QD and the combined placebo groups). In this summary, all AEs with an onset date after the first dose of study drug will be included, regardless of whether the AE occurred more than 30 days after the last dose of study drug.

### **10.2.1.3 TEAEs by Maximum Severity**

TEAEs will also be summarized by maximum severity by "as treated" treatment group and overall. If a subject has an AE with an unknown severity, then the subject will be

counted in the severity category of unknown, even if the subject has another occurrence of the same event with a severity present. The only exception is that if the subject has another occurrence of the same AE with the most extreme severity – severe. In this case, the subject will be counted under the severe category.

#### **10.2.1.4 TEAEs by Relationship**

TEAEs will also be summarized by relationship to Upadacitinib and Placebo, as assessed by the investigator, by "as treated" treatment group and overall. If a subject has a TEAE with an unknown relationship, then the subject will be counted in the relationship category of "unknown," even if the subject has another occurrence of the same event with a relationship present. The only exception is if the subject has another occurrence of the same TEAE with a relationship assessment of "reasonable possibility." In this case, the subject will be counted under the "reasonable possibility" category.

#### **10.2.1.5 Frequent ( $\geq 2\%$ ) Adverse Events and Reasonably Possibly Related Adverse Events by System Organ Class and Preferred Term**

TEAEs and reasonably possibly related AEs occurring for more than 2% of the subjects in any of the "as treated" treatment groups will be summarized by MedDRA PT in decreasing frequency separately.

#### **10.2.1.6 Adverse Events of Special Interest**

The Adverse Events of Special Interest (AESI) categories will be summarized and presented by "as treated" treatment group and overall using SOC and MedDRA PT. The AESI categories will be identified by the following search criteria per Standard MedDRA Queries (SMQs)/Company MedDRA Queries (CMQs) in [Table 8](#) below. Adjudicated cardiovascular events will be summarized and presented by treatment group using the CAC adjudicated categories.

**Table 8. AESI for Upadacitinib with SMQs/CMQs/PTs Searches**

<b>AESI</b>	<b>Type of MedDRA Query</b>	<b>Broad or Narrow Search</b>	<b>SMQ/CMQ Search Criteria</b>
Serious Infections	CMQ		"Infections" – Subset for SAEs
Opportunistic Infection excluding Tuberculosis and Herpes Zoster	CMQ		"Opportunistic Infection excluding Tuberculosis and Herpes Zoster"
Possible Malignancy	SMQ	Narrow	"Malignancies"
Malignancy	SMQ		"Malignant tumours"
Non-Melanoma Skin Cancer (NMSC)	SMQ	Narrow	Skin Malignant tumours (Narrow SMQ) removing Melanoma CMQ
Malignancy excluding NMSC			"Malignant tumours" SMQ removing NMSC output
Lymphoma	SMQ		"Malignant Lymphomas"
Hepatic Disorder	SMQ	Narrow	"Drug Related Hepatic Disorders"
Adjudicated Gastrointestinal Perforations	Output from adjudication		
Anemia	CMQ		"Non-Hemolytic and Non-Aplastic Anemias"
Neutropenia	CMQ		"Hematological Toxicity – Neutropenia"
Lymphopenia	CMQ		"Hematological Toxicity – Lymphopenia"
Herpes Zoster	CMQ		"Herpes Zoster"
Creatine Phosphokinase (CPK) Elevation	PT		Search only for the PT of "Blood creatine phosphokinase increased"
Renal Dysfunction	SMQ	Narrow	"Acute Renal, Failure"
Active Tuberculosis	CMQ		"Active Tuberculosis"
Adjudicated Cardiovascular Events	Output from CAC		
MACE*			
Cardiovascular Death			
Non-fatal Myocardial Infarction			
Non-fatal Stroke			

**Table 8. AESI for Upadacitinib with SMQs/CMQs/PTs Searches (Continued)**

AESI	Type of MedDRA Query	Broad or Narrow Search	SMQ/CMQ Search Criteria
Undetermined/Unknown Cause of Deaths			
Other Cardiovascular events			
Adjudicated Thrombotic Events	Output From CAC		
Venous Thromboembolic Events**			
Deep Vein Thrombosis			
Pulmonary Embolism			
Other Venous Thrombosis			
Arterial Thromboembolic Events (non-cardiac, non-neurologic)			

CAC = Cardiovascular Adjudication Committee; CMQ = company MedDRA query; PT = preferred term; SMQ = standard MedDRA query

\* MACE; Major Adverse Cardiovascular Events, defined as cardiovascular death, non-fatal myocardial infarction and non-fatal stroke.

\*\* Venous thromboembolic events (VTE) include deep vein thrombosis (DVT) and pulmonary embolism (PE) (fatal and non-fatal).

Additional AEs may be considered for tabulation/summary based on recommendations from Clinical and Safety as deemed appropriate.

### 10.2.2 Analysis of Long-Term Adverse Event Rates

Long-term adverse event rates will be analyzed using event rates adjusted by cumulative exposure and will be based on the actual treatment received at the time of AE occurrence. Starting with Amendment 4, all subjects will receive open-label upadacitinib 15 mg QD, including those currently on upadacitinib 30 mg QD. For subjects who previously received upadacitinib 30 mg QD, adverse events and exposure to upadacitinib 30 mg QD will be censored at the time of dose switch; subsequent adverse events and exposure



starting the day of first dose of upadacitinib 15 mg QD will be summarized under a separate group. The detailed treatment groups, including the handling of dose switch, are described in Section 8.1.

#### **10.2.2.1 Overview of Adverse Events Rates per 100 Patient-Years of Study Drug Exposure**

An overview of AEs per 100 patient-years of study exposure will be presented by treatment group and overall for the following AE categories.

- All TEAEs
- Treatment-emergent serious adverse events (SAEs)
- Treatment-emergent severe adverse events
- TEAEs reasonably possibly related to study drug
- TEAEs of special interest
- TEAEs leading to discontinuation of study drug
- TEAE leading to death

For this calculation, 1 year will be considered to be 365.25 days. For each treatment group, the numerator of the overall rate will be the total number of TEAEs reported for the event; that is, a subject can contribute more than one event to the numerator. For each treatment group, the denominator of the rates will be the total number of days exposed to study drug summed across all treated subjects divided by 365.25. Please refer to Section 6.0 for the calculation of study drug exposure. The AE rate per 100 patient-years of exposure will be calculated as  $([\text{numerator}/\text{denominator}]) * 100$ . The number of AEs reported (numerator), the total number of years of study drug exposure (denominator), and the AE rate per 100 patient-years will be presented for each treatment group and overall.

In the AE overview summary, any event with an unknown severity will be considered as severe and any AE with an unknown relationship will be considered as having "reasonable possibility" of being related to study drug.

Additional AEs may be considered for tabulation/summary based on recommendations from Clinical and Safety as deemed appropriate.

For TEAEs of special interest, the point estimate and 95% CI (using normal approximation) will be provided for the treatment difference in AE rate per 100 patient-years between each Upadacitinib dose group and the combined placebo group.

#### **10.2.2.2 Adverse Events Rates per 100 Patient-Years of Study Drug Exposure by SOC and PT**

For each treatment group, the TEAE rate per 100 patient-years of exposure will be calculated overall, for each SOC and each PT, for each of the following events:

- All TEAEs
- Treatment-emergent serious adverse events (SAEs)
- Treatment-emergent severe adverse events
- TEAEs reasonably possibly related to study drug
- TEAEs leading to discontinuation of study drug
- TEAE leading to death

For this calculation, 1 year will be considered to be 365.25 days. For each treatment group, the numerator of the overall rate, the SOC rate, or the PT rate, will be the total number of TEAEs reported overall, for the SOC, or for the PT, respectively; that is a subject can be counted more than once overall, for a SOC, and for a PT. For each treatment group, the denominator of the rates will be the total number of days exposed to study drug summed across all treated subjects divided by 365.25. Please refer to Section 6.0 for the calculation of study drug exposure. The AE rate per 100 patient-years of exposure will be calculated as  $[(\text{numerator}/\text{denominator})]*100$ . The number of AEs reported (numerator), the total number of years of study drug exposure (denominator), and the AE rate per 100 patient-years will be presented overall, for each SOC, and for each PT for each treatment group.

### **10.2.2.3 Adverse Events of Special Interest Rates per 100 Patient-Years of Study Drug Exposure**

The Adverse Events of Special Interest (AESI) categories will be summarized and presented for each treatment group and overall using SOC and MedDRA PT. The AESI categories will be identified as defined in [Table 8](#). Adjudicated cardiovascular events will be summarized and presented by treatment group using the CAC adjudicated categories.

For each treatment group, the Adverse Events of Special Interest (AESI) rate per 100 patient-years of exposure will be calculated overall, for each SOC and each PT, for each of the AESI listed in [Section 10.2.1.6](#). For this calculation, 1 year will be considered to be 365.25 days. For each treatment group, the numerator of the overall rate, the SOC rate, or the PT rate, will be the total number of TEAEs reported overall, for the SOC, or for the PT, respectively; that is a subject can be counted more than once overall, for a SOC, and for a PT.

For each treatment group, the denominator of the rates will be the total number of days exposed to study drug summed across all treated subjects divided by 365.25. Please refer to [Section 6.0](#) for the calculation of study drug exposure. The AE rate per 100 patient-years of exposure will be calculated as  $[(\text{numerator}/\text{denominator})] * 100$ . The number of AEs reported (numerator), the total number of years of study drug exposure (denominator), and the AE rate per 100 patient-years will be presented overall, for each SOC, and for each PT for each treatment group.

### **10.2.2.4 Listing of Serious Adverse Events (Including Deaths) and Adverse Events Leading to Study Drug Discontinuation**

All serious adverse events (SAEs), deaths, and adverse events leading to discontinuation of study drug will be listed.

### **10.3 Analysis of Laboratory Data**

#### **10.3.1 Variables and Units**

All laboratory parameters to be collected in this study are listed below. Laboratory parameters will be reported using the standard international (SI) units.

**Table 9. List of Laboratory Variables**

---

<b>Laboratory Variables</b>
<b>Hematology</b>
White Blood Cell (WBC) Count
Red Blood Cell (RBC) Count
Hemoglobin
Hematocrit
Platelets count
Neutrophils
Basophils
Eosinophils
Lymphocytes
Monocytes
Bands
<b>Chemistry</b>
Total Bilirubin
Alkaline Phosphatase (ALP)
Aspartate aminotransferase (AST)
Alanine aminotransferase (ALT)
Total Protein
Albumin
Glucose
Triglycerides
Blood Urea Nitrogen (BUN)
Creatinine
Uric acid
Sodium

---

**Table 9. List of Laboratory Variables**

---

<b>Laboratory Variables</b>
<b>Chemistry (Continued)</b>
Potassium
Calcium
Inorganic Phosphorus
Creatine Phosphokinase (CPK)
Chloride
Bicarbonate
Cholesterol
LDL cholesterol
HDL cholesterol
LDL/HDL ratio
Cholesterol/HDL ratio
<b>Urinalysis</b>
Specific Gravity
pH
Protein
Glucose
Ketones
Blood
Microscopic Examination (if needed)
Urobilinogen
Bilirubin
Leukocytes
Nitrites
<b>Other</b>
hs-CRP
QuantiFERON-TB Gold <sup>a</sup>
IgG and IgM
ESR
TBNK
Additional TBNK

---

a. For annual follow-up QFT is captured only for those with negative QFT at Screening.

### **10.3.2 Analysis of Laboratory Data by Week 12**

The laboratory data will be summarized by the "as treated" treatment groups (Upadacitinib 15 mg QD, Upadacitinib 30 mg QD, and combined placebo groups) and overall.

#### **10.3.2.1 Assessment of Mean Change from Baseline and Percentage Change from Baseline in Clinical Laboratory Variables**

Analyses of mean change from baseline in continuous hematology, chemistry, and urinalysis variables which are measured longitudinally will be performed by visits and by "as treated" treatment group. For each change from baseline analysis, the following summary statistics will be presented for each treatment group: sample size, baseline mean, visit mean, and the mean, standard deviation, and median of the changes from baseline. An ANOVA model with treatment as a factor will be used to test statistical significance for the change from baseline mean among different treatment groups.

In addition, similar analyses will be conducted for percentage change from baseline in LDL, HDL and cholesterol.

#### **10.3.2.2 Assessment of Shift from Baseline in Clinical Laboratory Variables**

The baseline and post-baseline laboratory observations will be categorized as Grade 1, Grade 2, Grade 3, and Grade 4 according to OMERACT criteria (Rheumatology Common Toxicity Criteria v.2.0). For creatine phosphokinase and creatinine, NCI CTC criteria will be used.

For each laboratory variable, shift tables will be generated that cross tabulate the subjects as deemed appropriate by "as treated" treatment group:

- Category of the baseline value versus category of the final value.
- Category of the baseline value versus maximum category.
- Category of the baseline value versus minimum category.

Note that the minimum/maximum category is used, rather than the category of the minimum/maximum value. The two may be different due to variation in the reference range.

No statistical tests will be performed for this analysis.

### **10.3.2.3 Assessment of Potentially Clinical Significant Laboratory Values**

The criteria for potentially clinically significant laboratory values will be determined by OMERACT criteria of Grade 3 or 4. For creatine phosphokinase and creatinine, NCI CTC criteria will be used.

The number and percentage of subjects meeting the criteria for potentially clinically significant laboratory values will be summarized by "as treated" treatment group and overall. Comparisons of the percentage of subjects experiencing a value meeting the criteria between treatment groups will be performed using Fisher's exact tests. Only p-values  $\leq 0.100$  when rounded to three digits will be presented.

### **10.3.2.4 Assessment of Liver Elevations**

According to FDA's Guidance for Industry "Drug-Induced Liver Injury: Premarketing clinical evaluation" (July 2009), when aminotransferase (AT) abnormalities indicating hepatocellular injury are accompanied by evidence of impaired hepatic function (bilirubin elevation  $> 2 \times \text{ULN}$ ), in the absence of evidence of biliary obstruction (i.e., significant elevation of ALP) or some other explanation of the injury (e.g., viral hepatitis, alcohol hepatitis), the combined finding (i.e., Hy's Law cases) represents a signal of a potential for the drug to cause severe DILI.

For the purpose of assessing for potential Hy's law cases, the frequencies and percentages of subjects with post baseline liver specific function test values that meet the following criteria of potential clinical interest will be summarized by "as treated" treatment group:

- $\text{ALT} \geq 3 \times \text{ULN}$

- $ALT \geq 5 \times ULN$
- $ALT \geq 10 \times ULN$
- $ALT \geq 20 \times ULN$
- $AST \geq 3 \times ULN$
- $AST \geq 5 \times ULN$
- $AST \geq 10 \times ULN$
- $AST \geq 20 \times ULN$
- $TBL \geq 2 \times ULN$
- Alkaline phosphatase  $\geq 1.5 \times ULN$
- $ALT$  and/or  $AST \geq 3 \times ULN$  and concurrent  $TBL \geq 1.5 \times ULN$
- $ALT$  and/or  $AST \geq 3 \times ULN$  and concurrent  $TBL \geq 2 \times ULN$

### **10.3.3 Analysis of Long-Term Laboratory Data**

#### **10.3.3.1 Assessment of Mean Change from Baseline and Percentage Change from Baseline in Clinical Laboratory Variables**

Analyses of mean change from baseline in continuous hematology, chemistry, and urinalysis variables which are measured longitudinally will be performed by visits and by "as treated" treatment group sequences as described in Section 10.1. For each change from baseline analysis, the following summary statistics will be presented for each treatment group sequence: sample size, baseline mean, visit mean, and the mean, standard deviation, and median of the changes from baseline.

In addition, similar analyses will be performed for percentage change from baseline in LDL-C, HDL-C and total cholesterol.

Starting with Amendment 4, all subjects will receive open-label upadacitinib 15 mg QD, including those currently on upadacitinib 30 QD. Mean change from baseline in laboratory values for subjects who switched from upadacitinib 30 mg QD to 15 mg QD will be censored at the time of dose switch, and mean change from baseline for values



post switch will be summarized separately, as described in Section 10.1. The original study baseline will be used for calculating change from baseline.

### **10.3.3.2 Assessment of Potentially Clinically Significant Laboratory Values**

Long-term laboratory data will be summarized based on the number and percentage of subjects meeting the criteria for potentially clinically significant laboratory values and by the actual treatment received at the time of the event occurrence. Starting with Amendment 4, all subjects will receive open-label upadacitinib 15 mg QD, including those currently on upadacitinib 30 mg QD. The treatment groups for summarizing potentially clinically significant laboratory values are the same as the ones for long-term AE analysis as described in Section 8.1 and Section 10.2.2. A subject can be counted under different treatment groups if he/she switched treatment and experienced potentially clinically significant laboratory values under different treatment groups.

In the evaluation of potentially clinically significant laboratory values, the baseline value will be determined by the last non-missing measurement recorded on or before the date of the first dose of study drug in the corresponding treatment group (which may be different than the first dose of study drug received in the study). For example, for a subject who started on Placebo and switched to Upadacitinib 15 mg QD, lab values under Upadacitinib 15 mg QD exposure would be evaluated against the baseline value defined as the last non-missing measurement recorded on or before the date of the first dose of Upadacitinib 15 mg QD. For subjects who switched from upadacitinib 30 mg QD to upadacitinib 15 mg QD, lab values under upadacitinib 15 mg QD exposure would still be evaluated against the baseline defined based on the first dose of Upadacitinib 30 mg QD.

A listing of all subjects with any laboratory determination meeting OMERACT criteria of Grade 3 or 4 will be provided by Grade. For creatine phosphokinase and creatinine, NCI CTC criteria will be used. For each of these subjects, the whole course of the respective parameter will be listed.

### **10.3.3.3 Assessment of Liver Elevations**

The frequencies and percentages of subjects with post-baseline liver-specific function test values that meet the criteria of potential clinical interest (as described in Section 10.3.2.4) will be summarized by the actual treatment received at the time of the event occurrence. Starting with Amendment 4, all subjects will receive open-label upadacitinib 15 mg QD, including those currently on upadacitinib 30 QD. The treatment exposure groups for summarizing liver elevations are the same as the ones for long-term AE analysis as described in Section 8.1 and Section 10.2.2.

A subject can be counted under different treatment groups if he/she switched treatment and experienced potentially clinical significant laboratory values under different treatment groups.

A listing of potentially clinically significant liver elevations based on criteria specified above will be provided. For each of these subjects, the whole course of the respective parameter will be listed.

## **10.4 Analysis of Vital Signs**

### **10.4.1 Variables and Criteria Defining Abnormality**

Vital sign variables include sitting systolic blood pressure, sitting diastolic blood pressure, pulse rate, respiratory rate, body temperature, and weight. The criteria for potentially clinically significant vital sign findings are presented in Table 10.

**Table 10. Criteria for Potentially Clinically Significant Vital Sign Findings**

Vital Sign	Category	Criteria for Potential Clinically Significant Vital Signs
Systolic blood pressure	Low	Value $\leq$ 90 mmHg and decrease $\geq$ 20 mmHg from Baseline
	High	Value $\geq$ 160 mmHg and increase $\geq$ 20 mmHg from Baseline
Diastolic blood pressure	Low	Value $\leq$ 50 mmHg and decrease $\geq$ 15 mmHg from Baseline
	High	Value $\geq$ 105 mmHg and increase $\geq$ 15 mmHg from Baseline
Weight	High	> 7% increase from baseline
	Low	> 7% decrease from baseline

#### 10.4.2 Analysis of Vital Sign by Week 12

Analyses of mean change from baseline in continuous vital sign variables which are measured longitudinally will be performed by visits and by the "as treated" treatment groups of Upadacitinib 15 mg QD, Upadacitinib 30 mg QD, and combined placebo groups. For each change from baseline analysis, the following summary statistics will be presented for each treatment group: sample size, baseline mean, visit mean, and the mean, standard deviation, and median of the changes from baseline. An ANOVA model with treatment as factor, will be used to test statistical significance for the change from baseline mean among different treatment groups.

The number and percentage of subjects meeting the criteria for potentially clinically significant vital sign values will be summarized by "as treated" treatment group and overall.

#### 10.4.3 Analysis of Long-Term Vital Sign

Analyses of mean change from baseline in continuous vital signs variables which are measured longitudinally will be performed by visits and by "as treated" treatment group sequences as described in Section 10.1. For each change from baseline analysis, the following summary statistics will be presented for each treatment group: sample size, baseline mean, visit mean, and the mean, standard deviation, and median of the changes from baseline.

Long-Term Vital Sign will also be summarized based on the number and percentage of subjects meeting the criteria for potentially clinical significant vital sign values and by the actual treatment received at the time of the event occurrence. The treatment groups are the same as the ones for long-term AE analysis as described in Section 8.1 and Section 10.2.2. A subject can be counted under different treatment groups if he/she switched treatment and experienced potentially clinical significant laboratory values under different treatment groups.

In the evaluation of potentially clinically significant vital sign values, the baseline value will be determined by the last non-missing measurement recorded on or before the date of the first dose of study drug in the corresponding treatment group, similarly as described in Section 10.3.3.2.

Starting with Amendment 4, all subjects will receive open-label upadacitinib 15 mg QD, including those currently on upadacitinib 30 QD. Mean change from baseline in vital signs for subjects who switched from upadacitinib 30 mg QD to 15 mg QD will be censored at the time of dose switch, and mean change from baseline for values post switch will be summarized separately, similarly as described in Section 10.3.3.1. The treatment groups for summarizing potentially clinical significant vital sign values are the same as the ones for long-term AE analysis as described in Section 8.1 and Section 10.2.2. For the purpose of evaluating potentially clinical significant vital sign values, for subjects who switched from upadacitinib 30 mg QD to upadacitinib 15 mg QD, baseline is defined based on the first dose of upadacitinib 30 mg QD, similarly as described in Section 10.3.3.2.

A listing of all subjects with any vital sign values meeting the criteria for potentially clinically significant vital signs will be provided. For each of these subjects, the whole course of the respective parameter will be listed.

## 11.0 Summary of Changes

### 11.1 Summary of Changes between the Previous Version and the Current Version

The primary efficacy analysis and Period 1 reporting have been completed under the SAP version 2.0. The current SAP update applies only to future reporting of long-term analysis.

1. Updated throughout the SAP to align with Protocol Amendment 4, 5, and 6, including handling of dose switch from upadacitinib 30 mg QD to 15 mg QD (hereafter referred to as "dose switch") and change of study length from 240 to 260 weeks.
2. Updated Section 7.0 to clarify analysis details and incorporate additional summary of dose switch.
3. Updated Section 8.1 study drug exposure groups to accommodate dose switch.
4. Updated Section 9.1.1 and Section 9.3 to incorporate handling of dose switch for long-term efficacy analysis.
5. Updated Section 9.1.2 to describe the missing data handling approach for the additional sensitivity analysis using longitudinal models for long-term efficacy.
6. Updated Section 9.3 to incorporate the additional sensitivity analysis for long-term efficacy.
7. Added language to clarify analysis details in Section 10.2.1.1, Section 10.2.1.6, Section 10.2.2.1, Section 10.2.2.3, Section 10.3.3.2, and Section 10.4.3.
8. Updated Section 10.2.1.6 and Section 10.4.1 to align with the latest upadacitinib AESI definitions in PSSAP V4.0.
9. Updated Section 10.1, Section 10.2.2, Section 10.3.3.1, Section 10.3.3.2, Section 10.3.3.3, and Section 10.4.3 to incorporate handling of dose switch for long-term safety analysis.

10. Added [Appendix B](#) to describe analysis accounting for impact of COVID-19 pandemic.
11. Added Section [11.0](#) for summary of changes and Section [12.0](#) for SAP version history summary.

## 12.0 Version History

**Table 11. SAP Version History Summary**

Version	Date	Summary
1.0	27 Dec 2016	Original version (submitted to FDA to gain feedback).
2.0	29 Jun 2017	Updated to incorporate FDA feedback. Version 2.0 was used for the primary analysis.
3.0	18 Dec 2020	Updated to align with Protocol Amendment 4, and 5 and 6, including handling of dose switch from upadacitinib 30 mg QD to 15 mg QD and change of study length from 240 to 260 weeks. Included additional sensitivity analysis for long-term efficacy, and analyses due to COVID-19 impact.

## 13.0 Appendix

[Appendix A](#)

OMERACT Criteria

[Appendix B](#)

Statistical Analysis to Account for Impact of COVID-19 Pandemic

**Appendix A. OMERACT Criteria**

<b>Rheumatology Common Toxicity Criteria v.2.0</b>				
<b>Based on Woodworth TG, et al. Standardizing assessment of adverse effects in rheumatology clinical trials II. Status of OMERACT Drug Safety Working Group May 2006: OMERACT 8. Standardizing Assessment and Reporting of Adverse Effects in Rheumatology Clinical Trials: Enabling Description of Comparative Safety Profiles for Antirheumatic Therapies</b>				
	<b>1 – Mild</b>	<b>2 – Moderate</b>	<b>3 – Severe</b>	<b>4 – Includes Life Threatening</b>
	Asymptomatic, or transient Short duration (< 1 week) No change in life style No medication or OTC	Symptomatic Duration (1 – 2 weeks) Alter lifestyle occasionally Meds relieve. (may be prescription), Study drug continued	Prolonged symptoms, reversible, major functional impairment Prescription meds/partial relief May be hospitalized < 24 hr Temporary study drug discontinuation, or/and dose reduced	At risk of death Substantial disability, especially if permanent. Multiple meds Hospitalised > 24 hr Study drug discontinued
<b>A. Allergic/Immunologic</b>				
A1. Allergic reaction/hypersensitivity (includes drug fever)	Transient rash: drug fever < 38°C: transient, asymptomatic bronchospasm	Generalised urticaria responsive to meds; or drug fever > 38°C, or reversible bronchospasm	Symptomatic bronchospasm requiring meds; symptomatic urticaria persisting with meds, allergy related oedema/angioedema	Anaphylaxis, laryngeal/pharyngeal oedema, requiring resuscitation
A2. Autoimmune reaction	Serilogic or other evidence of autoimmune reaction, but patient asymptomatic: all organ function normal and no treatment is required (e.g., vitiligo)	Evidence of autoimmune reaction involving a non-essential organ or functions, requiring treatment other than immunosuppressive drugs (e.g., hypothyroidism)	Reversible autoimmune reaction involving function of a major organ or toxicity requiring short term immunosuppressive treatment (e.g., transient colitis or anaemia)	Causes major organ dysfunction, or progressive, not reversible, or requires long-term administration of high dose immunosuppressive therapy

A3. Rhinitis (includes sneezing, nasal stuffiness, post-nasal discharge)	Transient, non-prescription meds relieve	Prescription med. required, slow	Corticosteroids or other prescription med. with persistent disabling symptoms such as impaired exercise tolerance	NA
A4. Serum sickness	Transient, non-prescription meds relieve	Symptomatic, slow response to meds (e.g., oral corticosteroids)	Prolonged; symptoms only partially relieved by meds; parenteral corticosteroids required	Major organ dysfunction, requires long-term high-dose immunosuppressive therapy
A5. Vasculitis	Localised, not requiring treatment; or rapid response to meds; cutaneous	Symptomatic, slow response to meds (e.g., oral corticosteroids)	Generalised, parenteral corticosteroids required or/and short duration hospitalisation	Prolonged, hospitalisation, ischemic changes, amputation
<b>B. Cardiac</b>				
B1. Arrhythmia	Transient, asymptomatic	Transient, but symptomatic or recurrent, responds to meds	Recurrent/persistent; maintenance prescription	Unstable, hospitalisation required, parenteral meds
B2. Cardiac function decreased	Asymptomatic decline in resting ejection fraction by > 10%, but < 20% of baseline value	Asymptomatic decline of resting ejection fraction $\geq$ 20% of baseline value	CHF responsive to treatment	Severe or refractory CHF
B3. Edema	Asymptomatic (e.g., 1 + feet/calves), self-limited, no therapy required	Symptomatic (e.g., 2 + feet/calves), requires therapy	Symptoms limiting function (e.g., 3 + feet/calves, 2 + thighs), partial relief with treatment prolonged	Anasarca; no response to treatment
B4. Hypertension (new onset or worsening)	Asymptomatic, transient increase by > 20 mmHg (diastolic) or to > 150/100 if previously normal, no therapy required	Recurrent or persistent increase > 150/100 or by > 10 mmHg (diastolic), requiring and responding readily to treatment	Symptomatic increase > 150/100, > 20 mmHg, persistent, requiring multi agency therapy, difficult to control	Hypertensive crisis



B5. Hypotension (without underlying diagnosis)	Transient, intermittent, asymptomatic, orthostatic decrease in blood pressure > 20 mmHg	Symptomatic, without interference with function, recurrent or persistent > 20 mmHg decrease, responds to treatment	Syncope or symptomatic, interferes with function, requiring therapy and sustained medical attention, dose adjustment or drug discontinuation	Shock
B6. Myocardial ischaemia	Transient chest pain/ECG changes; rapid relief with nitro	Recurring chest pain, transient ECG ST-T changes; treatment relieves	Angina with infarction, no or minimal functional compromise, reduce dose or discontinue study drug	Acute myocardial infarction, arrhythmia or/and CHF
B7. Pericarditis/pericardial effusion	Rub heard, asymptomatic	Detectable effusion by echocardiogram, symptomatic NSAID required	Detectable on chest x-ray, dyspnoea; or pericardiocentesis; requires corticosteroids	Pulsus alternans with low cardiac output; requires surgery
B8. Phlebitis/thrombosis/Embolism (excludes injection sites)	Asymptomatic, superficial, transient, local, or no treatment required	Symptomatic, recurrent, deep vein thrombosis, no anticoagulant therapy required	Deep vein thrombosis requiring anticoagulant therapy	Pulmonary embolism
<b>C. General (constitutional)</b>				
C1. Fatigue/malaise (asthenia)	Increase over baseline; most usual daily functions maintained, short term	Limits daily function intermittently over time	Interferes with basic ADL, persistent	Unable to care for self, bed or wheelchair bound > 50% of day debilitating, hospitalisation
C2. Fever (pyrexia) (note: fever due to drug allergy should be coded as allergy)	Transient, few symptoms 37.7 – 38.5°C	Symptomatic, recurrent 38.6 – 39.9°C. Relieved by meds	≥ 40°C; ≤ 24 h, persistent symptoms; partial response to meds	≥ 40°C, debilitating, > 24 h, hospitalisation; no relief with meds
C3. Headache	Transient or intermittent, no meds or relieved with OTC	Persistent, recurring, non-narcotic analgesics relieve	Prolonged with limited response to narcotic medicine	Intractable, debilitating, requires parenteral meds

C4. Insomnia	Difficulty sleeping, short term, no interfering with function	Difficulty sleeping interfering with function, use of prescription med	Prolonged symptoms, with limited response to narcotic meds	Debilitating, hospitalisation; no relief with meds
C5. Rigors, chills	Asymptomatic, transient, no meds, or non-narcotic meds relieve	Symptomatic, narcotic meds relieve	Prolonged symptoms, with limited response to narcotic meds	Debilitating, hospitalisation; no relief with meds
C6. Sweating (diaphoresis)	Episodic, transient	Frequent, short term	Frequent, drenching, disabling	Dehydration, requiring IV fluids/hospitalization > 24 hrs
C7. Weight gain	5% – 9.9%	10% – 19.9%	20% – 30%	NA
C8. Weight loss	5% – 9.9%	10% – 19.9%	20% – 30%	NA
<b>D. Dermatologic</b>				
D1. Alopecia	Subjective, transient	Objective, fully reversible	Patchy, wig used, partly reversible	Complete, or irreversible even if patchy
D2. Bullous eruption	Localised, asymptomatic	Localised, symptomatic, requiring treatment	Generalised, responsive to treatment; reversible	Prolonged, generalised, or requiring hospitalisation for treatment
D3. Dry skin	Asymptomatic, controlled with emollients	Symptoms eventually (1 – 2 wks) controlled with emollients	Generalised, interfering with ADL > 2 wks, persistent pruritis, partially responsive to treatment	Disabling for extended period, unresponsive to ancillary therapy and requiring study drug discontinuation for relief
D4. Injection site reaction	Local erythema, pain, pruritis, < few days	Erythema, pain, oedema, may include superficial phlebitis, 1 – 2 wks	Prolonged induration, superficial ulceration; includes thrombosis	Major ulceration necrosis requiring surgery
D5. Petechiae (without vasculitis)	Few, transient asymptomatic	Dependent areas, persistent up to 2 wks	Generalised, responsive to treatment; reversible	Prolonged, irreversible, disabling

D6. Photosensitivity	Transient erythema	Painful erythema and oedema requiring topical treatment	Blistering or desquamation, requires systematic corticosteroids	Generalised exfoliation or hospitalisation
D7. Pruritis	Localised, asymptomatic, transient, local treatment	Intense, or generalised, relieved by systematic medication	Intense or generalised; poorly controlled despite treatment	Disabling, irreversible
D8. Rash (not bullous)	Erythema, scattered macular/popular eruption; pruritis transient; TOC or no meds	Diffuse macular/popular eruption or erythema with pruritis; dry desquamation; treatment required	Generalised, moist desquamation, requires systemic corticosteroids; responsive to treatment; reversible	Exfoliative or ulcerating; or requires hospitalisation; or parenteral corticosteroids
D9. Induration/fibrosis/Thickening (not sclerodermal)	Localized, high density on palpation, reversible, no effect on ADL and not disfiguring	Local areas < 50% body surface, not disfiguring, transient interference with ADL, reversible	Generalized, disfiguring, interferes with ADL, reversible	Disabling, irreversible, systemic symptoms
<b>E. Ear/Nose/Throat</b>				
E1. Hearing loss	Transient, intermittent, no interference with function	Symptomatic, treatment required, reversible	Interferes with function; incomplete response to treatment	Irreversible deafness
E2. Sense of smell	Slightly altered	Markedly altered	Complete loss, reversible	Complete loss, without recovery
E3. Stomatitis	Asymptomatic	Painful, multiple, can eat	Interferes with nutrition, slowly reversible	Requires enteral support; residual dysfunction
E4. Taste disturbance (dysgeusia)	Transiently altered; metallic	Persistently altered; limited effect on eating	Disabling, effect on nutrition	NA
E5. Tinnitus	Intermittent, transient, no interference with function	Requires treatment, reversible	Disabling, or associated with hearing loss	Irreversible deafness

E6. Voice changes (includes hoarseness, loss of voice, laryngitis)	Intermittent hoarseness, able to vocalise	Persistent hoarseness, able to vocalise	Whispered speech, slow return of ability to vocalise	Unable to vocalize for extended
E7. Xerostomia (dry mouth)	Transient dryness	Relief with meds	Interferes with nutrition, slowly reversible	Extended duration interference with nutrition, requires parenteral nutrition
<b>F. Eye/Ophthalmologic</b>				
F1. Cataract	Asymptomatic, no change in vision, non-progressive	Symptomatic, partial visual loss, progressive	Symptoms impairing function, vision loss requiring treatment, including surgery	NA
F2. Conjunctivitis	Asymptomatic, transient, rapid response to treatment	Symptomatic, responds to treatment, changes not interfering with function	Symptoms prolonged, partial response to treatment, interferes with function	NA
F3. Lacrimation increased (tearing, watery eyes)	Symptoms not requiring treatment, transient	Symptomatic, treatment required, reversible	Unresponsive to treatment with major effect on function	NA
F4. Retinopathy	Asymptomatic, non-progressive, no treatment	Reversible change in vision; readily responsive to treatment	Disabling change in vision ophthalmological findings reversible, sight improves over time	Loss of sight
F5. Vision changes (e.g., blurred, photophobia, night blindness, vitreous floaters)	Asymptomatic, transient, no treatment required	Symptomatic, vision changes not interfering with function, reversible	Symptomatic, vision changes interfering with function	Loss of sight

F6. Xerophthalmia (dry eyes)	Mild scratchiness	Symptomatic without interfering with function, requires artificial tears	Interferes with vision/function, corneal ulceration	Loss of sight
<b>G. Gastrointestinal</b>				
G1. Anorexia	Adequate food intake, minimal weight loss	Symptoms requiring oral nutritional supplementation	Prolonged, requiring iv support	Requires hospitalization for nutritional support
G2. Constipation	Asymptomatic, transient, responds to stool softener, OTC laxatives	Symptomatic, requiring prescription laxatives, reversible	Obstipation requiring medical intervention	Bowel obstruction. Surgery required
G3. Diarrhea	Transient, increase of 2 – 3 stools/day over pre-treatment (no blood or mucus), OTC agents relieve	Symptomatic, increase 4 – 6 stools/day, nocturnal stools, cramping, requires treatment with prescription meds	Increase > 6 stools/day, associated with disabling symptoms, e.g., incontinence, severe cramping, partial response to treatment	Prolonged, dehydration, unresponsive to treatment, requires hospitalization
G4. Dyspepsia (heartburn)	Transient, intermittent, responds to OTC antacids, H-2 blockers	Prolonged, recurrent, requires prescription meds, relieved by meds	Persistent despite treatment, interferes with function, associated with GI bleeding	NA
G5. GI bleed (gastritis, gastric or duodenal ulcer diagnosed-define aetiology)	Asymptomatic, endoscopic finding, haemocult + stools, no transfusion, responds rapidly to treatment	Symptomatic, transfusion $\leq 2$ units needed; responds to treatment	Haematemesis, transfusion 3 – 4 units, prolonged interference with function	Recurrent, transfusion > 4 units, perforation, requiring surgery, hospitalisation
G6. Haematochezia (rectal bleeding)	Haemorrhoidal, asymptomatic, no transfusion	Symptomatic, transfusion $\leq 2$ units, reversible	Recurrent, transfusion > 3 – 4 units	> 4 units, hypotension, requiring hospitalization
G7. Hepatitis	Laboratory abnormalities, asymptomatic, reversible	Symptomatic laboratory abnormalities, not interfering with function, slowly reversible	Laboratory abnormalities persistent > 2 wks, symptoms interfere with function	Progressive, hepato-renal, anasarca, pre-coma or coma

G8. Nausea, or nausea/vomiting (use diagnostic term)	Transient, intermittent, minimal interference with intake, rapid response to meds	Persistent, recurrent, requires prescription meds, intake maintained	Prolonged, interferes with daily function and nutritional intake, periodic iv fluids	Hypotensive, hospitalization, parenteral nutrition, unresponsive to out-patient management
G9. Pancreatitis	Amylase elevation, intermittent nausea/vomiting, transient, responds rapidly to treatment	Amylase elevation with abdominal pain, nausea, occasional vomiting, responsive to treatment	Severe, persistent abdominal pain with pancreatic enzyme elevation, incomplete or slow response to treatment	Complicated by shock, haemorrhage (acute circulatory failure)
G10. Proctitis	Perianal pruritus, haemorrhoids (new onset), transient, or intermittent, relieved by OTC meds	Tenesmus or ulcerations, anal fissure, responsive to treatment, minimal interference with function	Unresponsive to treatment, marked interference with function	Mucosal necrosis with haemorrhage, infection, surgery required
<b>H. Musculoskeletal</b>				
H1. Avascular necrosis	Asymptomatic MRI changes, non-progressive	MRI changes and symptoms responsive to rest and analgesia	MRI changes, symptoms requiring surgical intervention	Wheelchair bound; surgical repair not possible
H2. Arthralgia	Intermittent transient symptoms, no meds or relieved by OTC meds	Persistent or recurrent symptoms, resolve with meds, little effect on function	Severe symptoms despite meds impairs function	Debilitating, hospitalisation required for treatment
H3. Leg cramps	Transient, intermittent, does not interfere with function	Recurrent symptoms, minimally interferes with function or sleep, responds to meds	Persistent, prolonged interference with function or sleep, partial or no response to meds	NA
H4. Myalgia	Occasional; does not interfere with function	Frequent, requires meds (non-narcotic); minor effects on function	Major change in function/lifestyle, narcotic pain meds	Debilitating, profound weakness, requires wheelchair, unresponsive to meds

<b>I. Neuropsychiatric</b>				
11. Anxiety or Depression (mood alteration)	Symptomatic, does not interfere with function; no meds	Frequent symptoms, responds to meds; interferes with ADL at times	Persistent, prolonged symptoms, partial or no response to meds, limits daily function	Suicidal ideation or danger to self
12. Cerebrovascular ischaemia	NA	Single transient ischaemic event, responsive to treatment	Recurrent transient ischaemic events	Cerebrovascular vascular accident with permanent disability
13. Cognitive disturbance	Subjective symptoms, transient, intermittent, not interfering with function	Objective symptoms, persisting, interferes with daily function occasionally	Persistent, or worsening objective symptoms; interferes with routine daily routine	Debilitating/disabling and permanent; toxic psychosis
14. Depressed consciousness (somnia)	Observed, transient, intermittent, not interfering with function	Somnolence or sedation, interfering with function	Persistent, progressive, obundation, stupor	Coma
15. Inability to concentrate	Subjective symptoms, does not interfere with function	Objective findings, interferes with function	Persistent, prolonged objective findings or organic cause	NA
16. Insomnia (in absence of pain)	Occasional difficulty sleeping, transient intermittent, not interfering with function	Recurrent difficulty sleeping; requires meds for relief; occasional interference with function	Persistent or worsening difficulty sleeping; severely interferes with routine daily function	NA
17. Libido decreased	Decrease in interest	Loss of interest; influences relationship	Persistent, prolonged interfering with relationship	NA
18. Peripheral motor neuropathy	Subjective or transient loss of deep tendon reflexes; function maintained	Objective weakness, persistent, no significant impairment of daily function	Objective weakness with substantial impairment of function	Paralysis

I9. Peripheral sensory neuropathy (sensory disturbance)	Subjective symptoms without objective findings, transient, not interfering with function	Objective sensory loss, persistent, not interfering with function	Prolonged sensory loss or paraesthesias interfering with function	NA
I10. Seizure	NA	Recurrence of old seizures, controlled with adjustment of medication	Recurrence/exacerbation with partial response to medication	Recurrence not controlled, requiring hospitalization; new seizures
I11. Vertigo (dizziness)	Subjective symptoms, transient, intermittent, no treatment	Objective findings, recurrent, meds relieve, occasionally interfering with function	Persistent, prolonged, interfering with daily function; partial response to medication	Debilitating without response to medication, hospitalization
<b>J. Pulmonary</b>				
J1. Asthma	Occasional wheeze, no interference with activities	Wheezing, requires oral meds, occasional interference with function	Debilitating, requires nasal O <sub>2</sub>	Requires ventilator assistance
J2. Cough	Transient, intermittent, occasional OTC meds relieve	Persistent, requires narcotic or other prescription meds for relief	Recurrent, persistent coughing spasms without consistent relief by meds, interferes with function	Interferes with oxygenation; debilitating
J3. Dyspnea	Subjective, transient, no interference with function	Symptomatic, intermittent or recurring, interferes with exertional activities	Symptomatic during daily routine activities, interferes with function, treatment with intermittent nasal O <sub>2</sub> relieves	Symptomatic at rest, debilitating, requires constant nasal O <sub>2</sub>
J4. Pleuritic pain (pleurisy)	Transient, intermittent symptoms, no treatment or OTC meds relieve	Persistent symptoms, requires prescription meds for relief	Prolonged symptoms, interferes with function, requires frequent narcotic pain relief	Debilitation, requiring hospitalisation
J5. Pneumonitis (pulmonary infiltrates)	Asymptomatic radiographic changes, transient, no treatment required	Symptomatic, persistent, requiring corticosteroids	Symptomatic, requiring treatment including O <sub>2</sub>	Debilitating, not reversible; or requiring assisted ventilation



J6. Pulmonary function decreased (FVC or carbon monoxide diffusion capacity – DLCO)	76% – 90% of pre-treatment value	51% – 75% of pre-treatment value	26% – 50% of pre-treatment value	≤ 25% of pre-treatment value
<b>Laboratory Data</b>				
<b>K. Haematology</b>				
K1. Hgb (g/dl) decrease from pre-treatment	1.0 – 1.4	1.5 – 2.0	2.1 – 2.9, or Hgb < 8.0, > 7.0	≥ 3.0; or Hgb < 7.0
K2. Leukopenia (total WBC) × 1000	3.0 – 3.9	2.0 – 2.9	1.0 – 1.9	< 1.0
K3. Neutropenia (× 1000)	1.5 – 1.9	1.0 – 1.4	0.5 – 0.9	< 0.5
K4. Lymphopenia (× 1000)	1.5 – 1.9	1.0 – 1.4	0.5 – 0.9	< 0.5
K5. Platelets (× 1000)	75 – LLN	50 – 74.9	20 – 49.9; platelet transfusion required	< 20; recurrent platelet transfusions
<b>L. Chemistry</b>				
L1. Hypercalcaemia (mg/dl)	1.1 × ULN – 11.5	11.6 – 12.5	12.6 – 13.5; or symptoms present	> 13.5; or associated coma
L2. Hyperglycemia (mg/dl) Fasting	140 – 160	161 – 250	251 – 500	> 500, or associated with ketoacidosis
L3. Hyperkalaemia (mmol/l)***	5.5 – 5.9	6.0 – 6.4	6.5 – 7.0 or any ECG change	> 7.0 or any arrhythmia

L5. Hypocalcaemia (mg/dl)	0.9 × LLN – 7.8	7.7 – 7.0	6.9 – 6.5; or associated with symptoms	< 6.5 or occurrence of tetany
L6. Hypoglycemia (mg/dl)	55 – 64 (no symptoms)	40 – 54 (or symptoms present)	30 – 39 (symptoms impair function)	< 30 or coma
L7. Hyponatraemia (mmol/l)***	-	125 – 129	120 – 124	< 120
L8. Hypokalaemia (mg/dl)***	-	3.0 – 3.4	2.5 – 2.9	< 2.5
L9. CPK (also if polymyositis-disease ****)	1.2 – 1.9 × ULN	2.0 – 4.0 × ULN	4.0 × ULN with weakness but without life-threatening signs or symptoms	> 4.0 × ULN with signs or symptoms of rhabdomyolysis or life-threatening
L10. Serum uric acid	1.2 – 1.6 × ULN	1.7 – 2.9 × ULN	3.0 – 5.0 × ULN or gout	NA
L11. Creatinine (mg/dl) ****	1.1 – 1.3 × ULN	1.4* – 1.8 × ULN	1.9 – 3.0 × ULN	> 3.0 × ULN
L12. SGOT (AST)	1.2 – 1.5 × ULN	1.6 – 3.0 × ULN	3.1 – 8.0 × ULN	> 8.0 × ULN
L13. SGPT (ALT)	1.2 – 1.5 × ULN	1.6 – 3.0 × ULN	3.0 – 8.0 × ULN	> 8.0 × ULN
L14. Alkaline phosphatase	1.1 – 1.5** × ULN	1.6 – 3.0 × ULN	3.0 – 5.0 × ULN	> 5.0 × ULN
L15. T. bilirubin	1.1 – 1.4 × ULN	1.5 – 1.9 × ULN	2.0 – 3.0 × ULN	> 3.0 × ULN
L16. LDH	1.3 – 2.4 × ULN	2.5 – 5.0 × ULN	5.1 – 10 × ULN	> 10 × ULN
M. Urinalysis				
M1. Haematuria	Micro only	Gross, no clots	Clots, transfusion < 2 units	Transfusion required
M2. Proteinuria (per 24 h)	300 – 500 mg (tr/1+)	501 – 1999 mg (2+)	2 – 5.0 g (3+) nephrotic syndrome	5.0 g (4+) anasarca

M3. WBC in urine	NA	NA	Indicating acute interstitial nephritis	Associated with acute renal failure
M4. Uric acid crystals	Present without symptoms	NA	With stones or symptoms of stones (e.g., renal colic)	Causing renal outflow obstruction and hospitalization

\* in L11, 1.5 – 1.8 × ULN is changed to 1.4 – 1.8 × ULN.

\*\* in L14, 1.1 – 2.0 × ULN is changed to 1.1 – 1.5 × ULN.

\*\*\* in L3, L7 and L8, mg/dl is changed to mmol/l.

\*\*\*\*For CPK and Creatinine NCI CTC grading will be used. For CPK therefore the following gradings apply: Grade 1: > ULN – 2.5 × ULN; Grade 2: > 2.5 – 5.0 × ULN; Grade 3: > 5.0 – 10.0 × ULN; Grade 4: > 10.0 × ULN; For Creatinine the following gradings apply: Grade 1: > 1 – 1.5 × Baseline; > ULN – 1.5 × ULN; Grade 2: > 1.5 – 3.0 × Baseline; > 1.5 – 3.0 × ULN; Grade 3: > 3.0 baseline; > 3.0 – 6.0 × ULN; Grade 4: > 6.0 × ULN.

## **Appendix B. Statistical Analysis to Account for Impact of COVID-19 Pandemic**

### **1.0 Overview**

The COVID-19 pandemic is interfering with the conduct of many ongoing trials, with potential impacts on treatment duration and collection, analysis and the interpretation of clinical trial data. Some protocol-specified visits in the clinical trials may be impacted due to COVID-19 infection or logistical restrictions during the pandemic. For example, some scheduled visits may be missed due to self-quarantine or local government restrictions on travel; some visits may also be delayed or canceled due to healthcare resource constraints during the pandemic. Impacted visits due to COVID-19 will be recorded in the database.

This appendix describes the additional analyses and updates to existing analyses due to COVID-19 impact. At the time of COVID-19 pandemic, all study subjects are in Period 2 of the study. The primary efficacy analysis and Period 1 reporting have been completed in 2017 and are not affected by the COVID-19 pandemic. The analyses described in this appendix are only applicable to Period 2 and future reporting of the long-term analyses.

### **2.0 Patient Disposition**

Period 2 patient disposition and reason for discontinuation will be summarized as described in Section 7.0. For subjects who prematurely discontinued study drug or study participation, the reasons for discontinuation will be summarized with two additional categories capturing discontinuation due to COVID-19 infection or logistical restrictions related to the COVID-19 pandemic (as collected in CRF):

- Adverse event (AE)
- Withdrew consent
- Lost to follow-up
- Lack of efficacy
- COVID-19 infection
- COVID-19 logistical restrictions

- Other

In addition, the number and percentage of subjects with scheduled study visits affected by COVID-19 pandemic will be summarized by treatment group sequences. The impact on study visits will be summarized by the following categories (as collected in CRF) by visit:

- Missed visit
- Virtual visit
- In person, partial assessments done

### **3.0 Long Term Efficacy Analysis**

Missing data could occur due to various reasons, including missing visits/assessments, early withdrawal from the study, or missing due to COVID-19 infection or logistic restriction. The probability of having missed visits and missing data due to COVID-19 infection or logistical restrictions related to the COVID-19 pandemic can be reasonably assumed to be unrelated to the unobserved values. Therefore, for the purpose of statistical analysis, it is reasonable to assume that these missing data are missing at random (MAR) and the statistical models that require MAR assumption are appropriate.

As described in Section 9.1.2, longitudinal analysis models MMRM and GLMM will be used for long term efficacy analysis and will be maintained for long term efficacy analysis in the presence of missing data due to COVID-19.

### **4.0 Safety Analysis**

In listings of adverse events and deaths, a flag indicating whether the event or death was related to COVID-19 infection will be presented. A listing of COVID-19 related adverse events may be provided.

## 14.0           **References**

1.   Bretz F, Maurer W, Brannath W, et al. A graphical approach to sequentially rejective multiple test procedures. *Stat Med.* 28(4)2009;586-604.